La Rosa Holdings Corp. Reports 119% Year-Over-Year Increase in Revenue to $69.4 Million for Fiscal 2024; Surpassed Initial Revenue Guidance by Approximately $4.4 Million
La Rosa Holdings Corp. Strengthens Balance Sheet by Redeeming and Extinguishing a Large Portion of Outstanding Warrants
We have another past winner back on our radar for tomorrow’s session. Once upon a time back in 2023 this one was our biggest percentage gainer fo the entire year. A lot has happened since then .
Pull up LRHC right away and start your research. .
LRHC was established in 2004 as a comprehensive real estate services platform that seamlessly integrates residential brokerage, mortgage, title, and insurance services, bolstered by a cutting-edge educational support system.
The company boasts a distinctive brokerage model that places the agent at the center, providing them with a 100% commission structure.
Their strategic focus is to drive substantial growth through expansion, seizing the opportunities presented by the evolving trends in the agency model within the real estate industry.
La Rosa Realty’s core operations are primarily within the vast U.S. residential real estate market, which according to Zillow Research, reached a staggering $43.4 trillion in 2021. This marked a remarkable increase of $6.9 trillion since 2020 and more than doubled the levels seen a decade ago.
La Rosa Holdings’ serves as the holding company for a suite of agent-centric, technology-integrated, cloud-based, multi-service real estate companies.
The principal entity, La Rosa Realty, LLC, has earned its place in the “Top 75 Residential Real Estate Firms in the United States” as recognized by the National Association of Realtors (NAR), the leading trade association in the U.S. real estate industry.
The brainchild of the operation is CEO, Mr. Joseph La Rosa, a successful real estate developer, business and life coach, author, podcaster, and public speaker. The business is deeply rooted in his transformative philosophies of family, passion, and growth. Mr. La Rosa’s book, “Do It Now!“, serves as a roadmap to personal success and well-being, inspiring a community of successful realtors who have played a significant role in the business’s growth.
In addition to offering face-to-face residential and commercial real estate brokerage services to the public, the company strategically cross-sells technology-based products and services.
The business is structured around providing services to its agents and the public, encompassing residential and commercial real estate brokerage, franchising, real estate brokerage education and coaching, as well as property management.
The primary real estate brokerage operates under the name La Rosa Realty, complemented by a smaller presence under the licensed trade name Better Homes Realty.
The company has established five corporate real estate brokerage offices under the La Rosa Realty brand in Florida, along with 28 franchised real estate brokerage offices in six U.S. states and Puerto Rico.
Additionally, they have expanded globally with an international franchised office in Peru. These real estate offices, both corporate and franchised, are collectively staffed by over 2,380 licensed real estate brokers and sales associates.
La Rosa Holdings Corp. Reports 119% Year-Over-Year Increase in Revenue to $69.4 Million for Fiscal 2024; Surpassed Initial Revenue Guidance by Approximately $4.4 Million
Revenue for the Fourth Quarter of 2024 Increased 55% Year-Over-Year to $17.7 Million
Gross Profit Increased 110% Year-Over-Year to $6.0 Million in 2024
CELEBRATION, Fla., April 16, 2025 (GLOBE NEWSWIRE) — La Rosa Holdings Corp.(NASDAQ: LRHC) (“La Rosa” or the “Company”), a real estate and PropTech company, today provided a business update and reported financial results for the year ended December 31, 2024.
Key Financial Highlights
Total revenue increased 119% year-over-year to $69.4 million for the year ended December 31, 2024 from $31.8 million for the year ended December 31, 2023
Residential real estate services revenue increased $36.6 million to $57.0 million, or 179%, for the year ended December 31, 2024 from $20.5 million for the year ended December 31, 2023
Property management revenue increased by approximately $1.4 million to $11.1 million, or 15%, for the year ended December 31, 2024 from $9.7 million for the year ended December 31, 2023
Real Estate Brokerage Services (Commercial) revenue increased by approximately $212 thousand to $328 thousand, or approx. 183% for the year ended December 31, 2024from $116 thousand for the year ended December 31, 2023
Gross profit increased by approximately $3.1 million, or 110%, year-over-year, to $6.0 million for the year ended December 31, 2024 from $2.8 million for the year ended December 31, 2023.
Joe La Rosa, CEO of La Rosa, commented, “We are pleased to report a 119% increase in revenue for 2024 compared to 2023, and a 55% increase in Q4 2024 year-over-year compared to the same period in 2023. Gross profit also increased 110% to $6.0 million in 2024, driven by strategic acquisitions of real estate brokerage franchisees and growth in our agent network, which now exceeds 2,500 agents. Our scalable, agent-first brokerage model continues to attract top talent by offering flexible compensation options, including a revenue share program, a 100% commission structure with low fees, and additional income through ancillary services and technology solutions.
“We recently started expanding internationally with engagement of an area developer in Spain, unlocking new revenue opportunities and strengthening our global presence. In addition, we introduced LR Agent Advance, a new program that provides our agents with upfront access to pending commissions, supporting their growth while generating an additional recurring revenue stream for the Company.”
Mr. La Rosa continued, “Importantly, Nasdaq has granted us a 180-day extension to comply with the minimum bid price rule, giving us the necessary time to execute our strategic initiatives. We are on track to close our previously announced acquisition of a real estate brokerage firm, which generated $19 million in revenue in 2023 and, if consummated, is expected to bring a network of around 945 agents across multiple states. Significantly, our revenue forecast for 2025 revenue for $100 Million remains intact.
“Looking ahead, we are focused on achieving profitability in 2025 by expanding into new markets, acquiring additional brokerage firms, growing our agent base, and leveraging technology to drive operational efficiencies. We are confident in our strategy to deliver sustainable growth and maximize shareholder value,” concluded Mr. La Rosa.
The closings of the acquisitions mentioned in this press release are subject to, and contingent upon, the parties entering into their respective definitive agreements. There can be no assurances that these acquisitions will be consummated.
Financial Results
Total revenue for the year ended December 31, 2024, was $69.4 million compared to $31.8 million for the year ended December 31, 2023. Residential real estate services revenue increased by $36.6 million to $57.0 million, or 179%, in the year ended December 31, 2024, from $20.5 million for the year ended December 31, 2023. The increase was driven by $9.8 million of revenue from the eight (8) acquisitions completed during fiscal year 2024, in addition the increase was due to a full year of income from the six (6) acquired companies in 2023. Selling, general and administrative costs, excluding stock-based compensation, for the year ended December 31, 2024, were approximately $11.6 million, compared to $4.8 million for the year ended December 31, 2023. Net loss was $15.9 million, or $(0.79) basic and diluted loss per share, for the year ended December 31, 2024, compared to net loss of $9.3 million, or $(1.27) basic and diluted loss per share, for the year ended December 31, 2023.
INVESTMENT HIGHLIGHTS
2,400+ agents worldwide
35 offices worldwide
Became a top 75 residential real estate company in the U.S. in 2016
Future Opportunity
Offer additional services such as mortgage, title, homeowner’s insurance
Organic growth and expansion to further locations in the U.S. and internationally
Create or acquire additional proprietary technologies
Unique Business Model
Services include: Residential & Commercial real estate brokerages, franchising, real estate education & coaching, property management
Agent centric model
Proprietary technology for training and marketing
Financial Strength
History of profitability
Solid balance sheet
Strongly positioned to drive near-term and long-term shareholder value
La Rosa Holdings Corp. Strengthens Balance Sheet by Redeeming and Extinguishing a Large Portion of Outstanding Warrants
PUBLISHED
JAN 28, 2025 8:30AM EST
Celebration, FL, Jan. 28, 2025 (GLOBE NEWSWIRE) — La Rosa Holdings Corp.(NASDAQ: LRHC) (“La Rosa” or the “Company”), a holding company for six agent-centric, technology-integrated, cloud-based, multi-service real estate segments, today announced that it has fully redeemed and extinguished all of its outstanding warrants (the “Warrants”) previously issued to an institutional accredited investor (the “Holder”). These Warrants, which were exercisable for 2,446,634 shares of common stock of the Company, have now been terminated in their entirety and are no longer exercisable, in accordance with the terms of the Warrant Redemption and Cancellation Agreement (the “Redemption Agreement”) signed by the parties on January 22, 2025.
The Company initially issued these Warrants under the securities purchase agreements dated April 1, 2024, and July 16, 2024, as previously disclosed in the Company’s Current Reports on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on April 5, 2024, and July 19, 2024.
Joe La Rosa, CEO of La Rosa, commented, “This milestone marks a significant step in our mission to streamline our capital structure and enhance shareholder value. By fully redeeming and extinguishing these Warrants, we are reinforcing our commitment to building a solid foundation for the Company’s sustained growth and long-term success. We believe there is a significant disconnect between the market valuation and the true value of the Company. As we focus on eliminating debt and strengthening our balance sheet, we remain dedicated to achieving profitability in 2025 by acquiring additional real estate brokerage firms, growing our agent network, and expanding into new markets.”
In addition, Joe La Rosa, CEO of La Rosa Holdings Corp., will be featured in a podcast interview with Zack Morris on Wednesday, January 29th, 2025, at 4:00 PM EST. Click here to tune in.
The closings of the acquisitions mentioned in this press release are subject to, and contingent upon, the execution of definitive agreements and other related transaction documents by the parties, corporate approval and customary closing conditions. There can be no assurances that these transactions will be consummated.
Over 20 years of domestic and international experience in multiple industries
Former SVP, Treasurer, Investor Relations & Business Finance of a multinational company
ALEX SANTOS
CHIEF TECHNOLOGY OFFICER
BS Computer Science
25+ Years Web Development & Technology Solutions with experience creating secure and scalable web applications.
TIFFANY POLITE
DIRECTOR OF COACHING
5+ years in Real Estate industry as Agent and coach
10 years or management and coaching experience
PEDRO AGUILAR
DIRECTOR OF EDUCATION
7+ years in the Real Estate industry as Agent and coach
10+ years as Instructor for U.S. Marine Corps Recruiting to drive recruiting goals throughout nationwide Recruiting Stations
LISSETTE ORTOLANI
DIRECTOR OF RECRUITING
Recruiter, manager and trainer within the real estate and insurance fields with over 10 years of experience
BRIAN KIRKWOOD
DIRECTOR OF MARKETING
BS Business Administration
7 Years with The Walt Disney Company
Development and implementation of brand and marketing identity for multiple companies
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF NINE THOUSAND SEVEN HUNDRED FIFTY USD BY SHORE THING MEDIA LLC FOR A ONE DAY LRHC AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
USAU is Sitting on 44 million AuEq Proven & Probable oz Reserve!
Roth Capital Partners recently initiated coverage of the company with a Buy rating and a price target of $10, calling the company “undervalued” based on its CK Gold Project
USAU is sitting on $9.1 Million in Cash as of 1/31/25
This has been a great environment for Gold. Physical gold, gold stocks, gold ETF’s etc. have all been performing well. Gold giant Newmont Mining is up roughly 50% in 2025, among other big gold companies that are performing well.
We have a past winner back in the forefront for Wednesdays session. You will definitely remember this one.
We brought it to you back in November when it was sitting around 6.20.
Then we showed it to you again in mid January when it was a little over 7.50.
In early Feb again we said you should research this company while it was still under $8.
Since then we have seen this company top out at the 52 week high of 11.75!
Pretty good right?
USAU is sitting strong, hovering right around the 10 buck mark right now.
Why all the buzz about USAU? That really cannot be summed up in a sentence but there is no denying that this has been a “right place, right time scenario”.
Roth Capital Partners recently initiated coverage of the company with a Buy rating and a price target of $10, calling the company “undervalued” based on its CK Gold Project.
Paradigm Capital also had positive coverage, with a Speculative Buy rating and a target price of $16.50. Paradigm’s analysts highlighted that the CK Gold Project, now fully permitted and shovel-ready, is positioned to become Wyoming’s next major gold and copper mine.
We also saw HC Wainwright raise their price objective on U.S. Gold from $11.00 to $13.00 and gave the stock a “buy” rating in a research report In late November.
USAU is also sitting in the portfolio of significant Wall Street players like JP Morgan Chase & Co, Jane Street Group, Prospera Financial Services & Geode Capital Managment to name a few.
Commonwealth Equity Services LLC purchased a new stake in U.S. Gold Corp. in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 31,000 shares of the technology company’s stock, valued at approximately $190,000.
Gold has been constantly in the news cycle over the past few years now since inflation started running wild.
Many top analysts are saying that gold stocks are poised to perform well in 2025 due to a combination of global economic uncertainties, inflationary pressures, and a stable demand for safe-haven assets. Inflation concerns continue to exist, pushing investors toward gold as a store of value. Geopolitical tensions and economic volatility create an environment where gold remains an attractive hedge against risk. As demand for gold remains strong and production becomes more efficient, gold companies offer a compelling investment opportunity for those seeking exposure to the precious metal while benefiting from the potential upside of well-managed mining operations.
U.S. Gold Corp. (NASDAQ: USAU) is an emerging gold and copper exploration and development company positioned to benefit from the ongoing bull market in gold.
The company holds 100% interests in the CK Gold project, which consists of various mining leases and other mineral rights covering approximately 1,120 acres in Laramie County, Wyoming; the Keystone project that consists of 601 unpatented lode mining claims covering approximately 20 square miles in Eureka County, Nevada; and the Challis Gold project, which consists of 77 unpatented lode mining claims covering approximately 1,710 acres in Lemhi County, Idaho.
With a focus on shovel-ready projects and a strategic location in a mining-friendly jurisdiction, U.S. Gold Corp aims to capitalize on rising gold prices. The company generates revenue primarily through the development of its mineral assets, particularly the CK Gold Project in Wyoming.
This project is one of the few permitted and shovel-ready gold and copper endeavors in North America, allowing for a streamlined path to production!
The company’s Keystone project in Nevada is very unique. It is a standalone district-scale project, located near Barrick’s flagship Cortez complex. It has very similar geology and stratigraphy to its neighbor, Cortez. It is USAU’s belief that a number of significant gold deposits are hosted at Keystone, and it is eagerly awaiting market conditions to improve so that we can explore Keystone with the level of interest that it deserves. It is a company maker in its own right.
U.S. Gold Corp plans to leverage its gold and copper reserves to maximize profit margins. With rising gold prices and stable energy costs, the company stands to benefit significantly as market conditions favor gold mining operations.
USAU is one of the only permitted, shovel-ready gold/copper projects in North America that is yet to be developed. Producing companies are desperate to replace dwindling ounces from their production assets. Other companies are looking to increase their production profiles to garner a re-rating from the mining analysts. US Gold is in a unique situation due to this and the M&A interest it will generate as the mining sector gains momentum.
Jurisdiction: The company’s asset is in the safest mining jurisdiction on the planet-State of Wyoming land. Wyoming is a resource/mining friendly area, with no federal nexus. This was hugely important to the permitting process of the CK Gold project and its ongoing development.
US senior exchange listing:USAU trading on the NASDAQ affords the company the ability to access retail investors throughout the US as well as institutional investors globally. With a very tight share structure, the company is very well positioned to make the most out of this burgeoning bull market.
Copper:USAU’s copper component offers diversification of the asset for those who aren’t bullish on the gold-cycle.
Other value metrics around the CK project that have not been valued into the company yet. New generation is going to be key as USAU unlocks these value markers.
Properties
CK Gold Project – Near-Term Gold – Copper Producer
The CK Gold Project deposit is a development stage, large-tonnage, gold-copper deposit with high-grade mineralization exposed at the surface surrounded by a large, low-grade zone with potential for expanding resources.
The CK Gold Project was reportedly discovered in 1881, high-graded and saw limited mining. The first exploration work reported is drilling by ASARCO in 1938. Several additional rounds of drilling have been conducted since that time. In 1972 Henrietta Mines Ltd. acquired the property and completed a comprehensive program of exploration and development. In addition to drilling, an I.P. survey, geologic mapping, geochemical sampling, and metallurgical testing were conducted (Nevin, 1973). Drilling campaigns were conducted by Saratoga since 2006 and Strathmore since 2012, with a hiatus in drill exploration until the acquisition of the project by U.S. Gold Corp. from Energy Fuels in 2014. U.S. Gold Corp. conducted drilling in 2017, 2018, 2020 and is currently concluding its 2021 drilling program, focused on data collection to support post PFS and feasibility studies in 2022.
The CK Gold Project property is located in the Silver Crown mining district of southeast Wyoming, approximately 20 miles west of the city of Cheyenne, on the southeastern margin of the Laramie Range. The property comprises about 1,120 acres (2 square miles) and is 100% owned by U.S. Gold Corp. (NASDAQ: USAU).
In December 2021, the company released the project’s SK-1300 Technical Report Preliminary Feasibility Study, PFS (by Gustavson Associates LLC). The project offers the company near-term, open-pit production potential as well as compelling value.
Highlights:
1.44 million AuEq Proven & Probable oz Reserve
Advantageous infrastructure, located near major highways and railroads, facilitates easy transportation of materials to smelters. This infrastructure advantage enhances the project’s economic viability.
100K+ oz AuEq Annual Production Forecast – plus significant upside
Mineral Resource Expansion – open at depth and laterally
All In Sustaining Cost (AISC) of $800 AuEq/ oz over LOM
Low Strip Ratio – surface mineral outcrop with immediate revenue potential
Study Underway Analyzing Aggregate Potential
Final Stages of Permitting with WY government – no federal permits needed.
CK Gold Project Pre-Feasibility Study Summary*
*Source:SK-1300 TechnicalReport Pre-FeasibilityStudy on the CK Gold Project report date December 1, 2021 using $1625 Au, $3.25 Cu and $18 Ag. Please see “CautionaryNote ConcerningMineral Resources”in this presentation
The Copper Situation
Prefeasibility Study Highlights of Ck Gold also include a staggering copper amount:
M+I includes: Gold – 1.110 million ounces and Copper – 280 million lbs!!!
Why is this a big deal?
Because copper will be a big part of the clean revolution.
Besides clean energy technologies, several industries including construction, infrastructure, and defense use copper for its unique properties. The metal is critical in many fast-growing clean industries from the electric grid and electric vehicles to renewable technologies.
Copper is essential in electrical wiring and transportation and is playing an increasingly large role in alternative energy, as it is a crucial component in wind turbines, solar panels, and electric vehicles, which require four times as much copper as conventional gas vehicles!
Some of the world’s largest mining companies and metal traders are warning that by 2025, a massive shortfall will emerge for copper, which is now the world’s most critical metal due to its essential role in the green economy.
The deficit will be so large that The Financial Post stated that it could itself hold back global growth, stoke inflation by raising manufacturing costs and throw global climate goals off course.
The copper supply issue is scary. There may not be enough copper to go around for the millions of electric vehicles (EVs) expected to hit the roads, or to fuel wind turbines and solar power.
In fact, wind and solar energy use more copper than conventional forms of energy, such as coal, natural gas, and nuclear power plants. Conventional power plants require about one ton of copper to produced one megawatt of electricity, whereas wind and solar can require between three to five tons per megawatt!
To make matters worse, these numbers only reflect the amount of copper needed to build wind turbines or solar panels, and do not factor in the additional copper needed to transport the electricity generated from wind and solar facilities to the population centers that consume the electricity.
The Next Milestones for the CK Gold Project:
Publishing an updated Prefeasibility Study (“PFS”), now slated for early 2025;
Continuing onto a final Feasibility Study (“FS”), which has already been advanced but awaits completion of the updated PFS to verify optimizations announced in September, including a final decision on the preferable flotation technology; and
Development financing opportunities with several interested parties who have been following the Company’s progress with interest.
All these activities are planned to occur during 2025 and development, subject to suitable financing, could commence as soon as year-end 2025.
U.S. Gold Corp. Announces Inaugural Digbee Assessment Results
As U.S Gold Approaches Financing Activities for the CK Gold Project, the Assessment Demonstrates that the Company is on the Right Track to Satisfy Lenders
CHEYENNE, Wyo., Feb. 26, 2025 /PRNewswire/ — U.S. Gold Corp. (“U.S. Gold,” the “Company,” “we,” “our” or “us”) (NASDAQ: USAU), is pleased to announce the results of an independent assessment conducted by Digbee Limited (“Digbee”). Digbee’s platform provides companies a right-sized, future-looking set of globally aligned sustainability frameworks. Digbee evaluates a comprehensive range of factors—considering both a project’s context and the effectiveness of management actions—to assign a rating from AAA to D. The overall inaugural BBB score achieved by U.S. Gold, largely for its CK Gold Project, reflects the average across all assessment criteria. We believe this rating endorses our progress and confirms that we are on track to meet and exceed the risk review criteria set by financing entities.
Operating and conducting business responsibly, by respecting local communities, protecting the environment, and maintaining strong business practices is not just about gaining acceptance and following best practices; it’s also good business sense. Companies that embed responsibility into their core operations build stronger stakeholder relationships, mitigate risks, and create long-term value. This acceptance is not only necessary for securing permits but also for obtaining the social license to operate. To date, U.S. Gold has received permits to develop its CK Gold Project in southeast Wyoming, and as we progress toward securing project financing, development lenders require assurances that all potential project risks have been addressed. These risks can span a wide spectrum, including governance (ensuring the company adheres to established business practices), environmental (complying with laws, regulations, and practices to prevent and mitigate damage to natural surroundings), and social factors (engaging local communities and securing their acceptance of project development). Development lenders, through experience, have gathered criteria to evaluate whether risks have been addressed, and their investment is secure. The Digbee platform not only helps guide companies in their activities, but it also provides investors with some comfort through an independent review that confirms risks—measured against a wide range of criteria and international best practice—have been addressed.
George Bee, President and CEO of U.S. Gold, said, “Over the last four years, we have endeavored to do things ‘the right way,’ reaching out to the local community and authorities and taking care that our disturbances resulting from exploration activities are cleared up as we go along. That same responsible attitude and the desire to be a ‘good neighbor’ as we get into development and operation is top of mind. We are pleased to share the results of this independent assessment of our activities. The assessment shows where we can still do better, but overall the BBB rating at this early stage is a great endorsement that we are on the right track as we move toward development.”
Mr. Jamie Strauss, the founder and CEO of Digbee, commented, “U.S. Gold’s completion of the Digbee assessment underscores its commitment to responsible development and transparency. By proactively evaluating risks and opportunities, the Company is positioning itself to build long-term value while meeting the evolving expectations of investors and stakeholders. This is a crucial step in demonstrating leadership and resilience in today’s mining landscape.”
The results of the Digbee assessment are available and summarized on the Company’s website and can be accessed by following the link here.
Keystone Project
Discovering the next major gold opportunity on the Cortez Trend in Nevada!
An established gold mining jurisdiction
Produced ~4.47 M oz of gold produced in 2021 – approx. 78% of U.S. gold production *USFunds.com
6th largest gold producing “country” in the world, if Nevada were a country
Historically, Nevada has produced > 225M oz of gold, hosting numerous world-class deposits
“Elephant country”: >20M oz gold deposits
Pro-mining environment, geopolitical stability, major infrastructure Keystone Project Location Keystone exhibits many similarities to Barrick’s deposits to the north; similar host rock, stratigraphy, structure and Eocene intrusions
Priority Target Areas:
Consolidated an entire district on the Cortez Trend, NV – 20 square miles, 100% controlled by U.S. Gold Corp.
Never previously consolidated nor systematically explored by model -driven, modern -day exploration techniques
The extent and intensity of the alteration and the thickness of permissive rock packages encountered, highlight the potential of this district-scale mineral system
Systematic exploration has primed Keystone for discovery
Recent hyperspectral survey undergoing ground investigation for potential additional targets
Mr. Bee is a senior mining industry executive, with deep mine development and operational experience. He has an extensive career advancing world-class gold mining projects in eight countries on three continents for both major and junior mining companies. Most recently in 2018 Mr. Bee concluded a third term with Barrick Gold as Senior VP Frontera District in Chile and Argentina to advance Pascua Lama feasibility as an underground mine. This capped a 16-year history with Barrick Gold with positions that included Mine Manager at Goldstrike during early development and operations, Operations Manager at Pierina Mine taking Pierina from construction to operations, and General Manager of Veladero developing the project from advanced exploration through permitting, feasibility and into production.
With his Barrick experience and having had eight years in South Africa working underground gold with Anglo American and open pit copper with Rio Tinto at Palabora Mine, Mr. Bee was well placed to advance projects internationally and domestically as a senior executive. This led to his appointment to various board and leadership positions at various companies. As COO of Aurelian Resources in 2007, he was in charge of project development for Fruta del Norte in Ecuador until Aurelian was acquired by Kinross Gold in 2008. Post-acquisition, moving on from Kinross, where he had also previously worked from 1996 to 1998 advancing projects in El Salvador and Nevada, he joined Andina Minerals as CEO in 2009. Andina and its 6 million-ounce Volcan Gold Project in Chile was acquired by Hochschild in 2013. By this time Mr. Bee had been appointed to the boards of Peregrine Metals and later Stillwater Mining and Jaguar Mining. In 2014, he also assumed the role of Chief Executive Officer of Jaguar Mining, operating mines in Brazil, as the company emerged from a financial restructuring process.
Mr. Bee is a graduate of the Camborne School of Mines in Cornwall, United Kingdom and is a member of the Institute of Corporate Directors with an ICD.D designation.
Eric Alexander
CHIEF FINANCIAL OFFICER AND CORPORATE SECRETARY
Mr. Eric Alexander has over 30 years of corporate, operational and business experience, and over 15 years of mining industry experience. Previously he served as Corporate Controller of Helix Technologies, Inc., a publicly traded software and technology company from April 2019 to September 2020. Prior to that, he served as the Vice President Finance and Controller of Pershing Gold Corporation, a mining company (formerly NASDAQ: PGLC), from September 2012 until April 2019. Prior to that, Mr. Alexander was the Corporate Controller for Sunshine Silver Mines Corporation, a privately held mining company with exploration and pre-development properties in Idaho and Mexico, from March 2011 to August 2012. He was a consultant to Hein & Associates LLP from August 2012 to September 2012 and a Manager with Hein & Associates LLP from July 2010 to March 2011. He served from July 2007 to May 2010 as the Corporate Controller for Golden Minerals Company (and its predecessor, Apex Silver Mines Limited), a publicly traded mining company with operations and exploration activities in South America and Mexico. In addition to his direct experience in the mining industry, he has also held the position of Senior Manager with the public accounting firm KPMG LLP, focusing on mining and energy clients. Mr. Alexander has a B.S. in Business Administration (concentrations in Accounting and Finance) from the State University of New York at Buffalo and is also a licensed CPA.
Kevin Francis
VICE PRESIDENT – EXPLORATION & TECHNICAL SERVICES
Mr. Francis has held many senior roles within the mining industry, including VP of Project Development for Aurcana Corporation, VP of Technical Services for Oracle Mining Corporation, VP of Resources for NovaGold Resources and Principal Geologist for AMEC Mining and Metals. Most recently, he consulted to U.S. Gold Corp. as Principal of Mineral Resource Management LLC, a consultancy providing technical leadership to the mining industry, as well as the CK Gold Project through his association with Gustavson Associates (a member of WSP) since September 2020. Mr. Francis is a member of the Board of Directors of Texas Mineral Resources Corporation. Mr. Francis is a “Qualified Person” as defined by SEC S-K 1300 and Canadian NI 43-101 reporting standards and holds both an M.S. degree and a B.A. in geology from the University of Colorado.
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SIX THOUSAND SEVEN HUNDRED FIFTY USD BY SIDEWAYS FREQUENCY LLC FOR A ONE DAY USAU AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
We’re coming off another action-packed week in the markets — full of volatility, heavy swings, and uncertainty. But even in the chaos, some companies are showing resilience and moving steadily forward. One of those names you should be watching closely is NLS Pharmaceutics (NASDAQ: NLSP).
Why NLSP Stands Out
NLSP is a clinical-stage pharmaceutical company developing innovative therapies for patients with rare and complex central nervous system (CNS) disorders — particularly in areas where existing treatments are insufficient or non-existent.
One of the fastest-growing sectors in global healthcare is ADHD, a market projected to reach $70+ billion by 2032. NLSP’s lead candidate, Mazindol ER, directly addresses this space — and more.
Mazindol ER: A Phase 3-Ready Asset with Broad Potential
Mazindol ER is an extended-release formulation of a well-studied compound with a proven safety profile. It’s Phase 3-ready for both:
Attention Deficit Hyperactivity Disorder (ADHD)
Narcolepsy and Excessive Daytime Sleepiness (EDS)
With Orphan Drug Designation in both the U.S. and Europe, and a strong Phase 2 data package in hand, Mazindol ER is positioned to move swiftly through the regulatory pipeline. The upcoming AMAZE Phase 3 trial will focus on adult patients with narcolepsy, a $4.5 billion market projected by 2027.
Strategic Expansion: Tackling the Opioid Crisis
In a significant step beyond CNS and sleep disorders, NLS also holds a U.S. patent for the use of Mazindol ER in treating opioid use disorder, including heroin and fentanyl addiction. A preclinical study targeting fentanyl addiction is underway and is expected to yield promising results.
This positions NLSP within the $5 billion opioid addiction treatment market, a high-priority area for the U.S. government and public health institutions. With fentanyl-related overdoses now the leading cause of drug-related deaths in the U.S., the need for non-opioid alternatives has never been greater. Mazindol ER’s unique pharmacological profile — modulating dopaminergic and noradrenergic pathways without being addictive — makes it a compelling candidate in this space.
Corporate HIGHLIGHTS
Clean balance sheet: No debt, $3.2M raised, 12-month cash runway
Nasdaq compliance regained
Merger in progress: Binding term sheet signed with Kadimastem, a clinical-stage biotech with complementary assets and commercial expertise
Pipeline strength: Over 100 patents in 140+ countries covering CNS, ADHD, cancer fatigue, Parkinson’s, and more
Named Patient Program launched in Europe for idiopathic hypersomnia
Multiple partnerships: Including Université de Lausanne, University of Berne, Swiss Narcolepsy Network, and patient advocacy organizations such as Narcolepsy Network and Hypersomnia Foundation
Product Pipeline Highlights
Quilience® – Targeting EDS and cataplexy in narcolepsy
Nolazol® – In development for ADHD and related neurodevelopmental disorders
IsletRx (via merger with Kadimastem) – A regenerative cell therapy targeting insulin-dependent diabetes
Why This Matters
NLS isn’t just riding the momentum of emerging markets in ADHD and sleep disorders — they’re seeking to build long-term value through intelligent pipeline development, strategic IP, and a focus on real-world, unmet clinical needs. And now, with its entrance into the fight against opioid addiction, NLSP adds a compelling new dimension to its mission.
In a market that punishes hype and rewards substance, NLSP is on the path to quietly execute.
NLS Pharmaceutics CEO Issues Letter to Shareholders
ZURICH, March 10, 2025 /PRNewswire/ — NLS Pharmaceutics Ltd. (NASDAQ: NLSP), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, today issued a letter to its shareholder.
Dear Shareholders,
We are thrilled to share the significant progress and strategic milestones NLS Pharmaceutics has achieved, positioning our company for a transformative future in the biotechnology sector.
Strategic Merger with Kadimastem
In November 2024, we announced a definitive merger agreement with Kadimastem Ltd. (TASE: KDST) (“Kadimastem”), a clinical-stage cell therapy company specializing in “off-the-shelf” allogeneic cell products for neurodegenerative diseases and diabetes. This merger aims to create a Nasdaq-traded biotechnology company with a robust portfolio of advanced therapies. Both companies’ boards of directors have unanimously approved the transaction, with Kadimastem’s shareholders recently voting in favor and NLS major shareholders holding approximately 40% of NLSs’ common shares having signed support letters for the NLS shareholders’ meeting to be convened soon. We currently anticipate closing the merger in the second quarter of 2025, pending effectiveness of NLSs’ pending registration statement filed with the Securities and Exchange Commission (“SEC”), Nasdaq approval, NLSs’ shareholders’ approval and customary closing conditions.
Regulatory Filings and Approvals
We filed a Registration Statement on Form F-4 and subsequent amendment with the SEC, detailing the proposed merger with Kadimastem. This filing is a necessary step toward finalizing the merger and creating a combined entity focused on innovative therapies. In addition, we have submitted an application to list the merged company on Nasdaq under the name of “NucelX Ltd.”, with the future ticker of NCEL.
Advancements in Diabetes Treatment
In collaboration with iTolerance Inc., Kadimastem has successfully completed a pre-Investigational New Drug (“pre-IND”) meeting with the U.S. Food and Drug Administration(“FDA”) for iTOL-102, a potential breakthrough therapy for Type 1 Diabetes. This innovative approach combines Kadimastem’s IsletRx cells with iTolerance’s immunomodulator, aiming to cure Type 1 Diabetes without the need for lifelong immune suppression.
The diabetes treatment landscape has experienced significant growth, underscored by notable mergers and acquisitions. For instance, Novo Nordisk’s acquisition of Inversago Pharma for up to $1.075 billion highlights the strategic emphasis on developing novel therapies for obesity, diabetes, and related metabolic disorders. Similarly, Roche’s $2.7 billion acquisition of Carmot Therapeutics reflects their concerted effort to expand into the diabetes and obesity markets. Additionally, Sana Biotechnology has made significant advancements in the diabetes space, with early clinical data suggesting their hypo immune platform could enable insulin production without immunosuppression, positioning them as a potential leader in developing transformative treatments for type 1 diabetes. We believe that these developments underscore the sector’s robust growth and the immense potential it holds for innovative treatments.
Furthermore, we are expanding our diabetes treatment strategies beyond GLP-1 therapies. By integrating complementary approaches, we aim to address the multifaceted challenges of diabetes management, including neuroinflammation and metabolic resilience.
Advancements in Neurodegenerative Disease Treatment
Post-merger, we plan to prepare and initiate a Phase IIa multi-site clinical trial of AstroRx®, Kadimastem’s product candidate for Amyotrophic Lateral Sclerosis (ALS). This trial is slated to commence following the merger’s completion, marking significant progress in our neurodegenerative disease treatment pipeline.
Experienced International Leadership Team
We believe that Kadimastem contributes to the merger with its experienced international leadership team and board of directors, and with the teams prior experience developing medicine from the laboratory to the market. For example, Rebif®, a blockbuster drug invented by Professor Michel Revel, Chief Scientist at Kadimastem, in his capacity as a scientific investigator at the world-renowned Weizmann Institute of Science, was acquired by Merck Serono. In addition, Ronen Twito, Kadimastem’s Executive Chairman and Chief Executive Officer, brings extensive experience working in the U.S. capital market and M&A international market.
Advancements in DOXA R&D Programs
Our promising Dual Orexin Receptor Agonist (“DOXA”) platform has made significant strides. The development of AEX-41 and AEX-2 compounds showcases our dedication to addressing unmet needs in sleep-wake disorders. Preliminary studies have yielded promising results, reinforcing our confidence in these compounds’ potential to transform patient care.
Additional Pipeline Expansion and Research Initiatives
Our commitment to addressing critical health challenges remains steadfast:
Fentanyl Dependence Treatment: We have launched a preclinical program evaluating Mazindol ER as a treatment for fentanyl dependence, aiming to offer a non-opioid alternative in combating the opioid crisis.
Advancing Scientific Research: Our recent submissions to and upcoming poster presentation at the American Society of Clinical Psychopharmacology’s 2025 Annual Meeting highlight our commitment to innovative therapeutic strategies and groundbreaking research.
Financial Resilience and Growth
We have fortified our financial foundation through strategic initiatives:
Nasdaq & Strong Financial Position
We carry zero long-term debt, a rarity among biopharmaceutical companies. This strong financial position provides us with flexibility to execute our strategic goals without financial constraints.
We raised approximately $4.2 million pursuant to private placements in October and December 2024, at a premium to market price. We currently believe that the amounts raised in these private placements has extended our operational runway to approximately 18 months.
This financial stability empowers us to accelerate clinical development, pursue strategic partnerships, and advance our innovative pipeline with confidence.
Looking Ahead
The momentum generated by these developments underscores our commitment to delivering life-changing therapies. We aim to capitalize on emerging opportunities within the dynamic biotechnology landscape, driving NLS Pharmaceutics toward a future of unparalleled success.
As we embark on this exciting new chapter, we remain laser-focused on:
Building an international, strong, well-balanced pipeline and top-notch biotechnology company
Delivering life-changing therapies for patients worldwide
Expanding our pipeline through innovation & strategic collaborations
Maximizing shareholder value by maintaining a strong financial position
We extend our deepest gratitude to our shareholders, partners, and supporters for your trust and commitment. Together, we are building a future of unparalleled success for NLS Pharmaceutics.
Sincerely,
Alex ZwyerChief Executive Officer
NLS Pharmaceutics (NASDAQ: NLSP)
PIPELINE
NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence
Centers for Disease Control and Prevention (the “CDC”) reported 105,007 drug overdose deaths – with 90% involving synthetic opioids like fentanyl
Mazindol ER potentially offers a non-opioid alternative, addressing the underlying neurochemical imbalances associated with fentanyl addiction.
Mazindol ER is patent protected beyond September 2038
ZURICH, Jan. 28, 2025 /PRNewswire/ — NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company dedicated to developing therapies for rare and complex central nervous system disorders, is proud to announce the launch of a preclinical program evaluating Mazindol ER (Extended-Release) as a novel treatment for fentanyl dependence. Fentanyl dependence is a major global health crisis and was recently declared a national public health emergency by the new Trump administration. In 2023, the CDC reported 105,007 drug overdose deaths with 90% involving synthetic opioids like fentanyl.
“The opioid epidemic, and specifically the rise of fentanyl dependence, presents an urgent medical need for innovative, non-opioid treatment approaches,” said Alex Zwyer, Chief Executive Officer of NLS. “We are committed to exploring the unique pharmacological profile of Mazindol, which targets multiple neurotransmitter systems implicated in opioid addiction. This preclinical program represents an important step in developing a potentially transformative therapy.”
Highlights of the Preclinical Program Mazindol, a tetracyclic compound with a distinct pharmacological profile, has shown potential in mitigating opioid dependence by acting on multiple neurotransmitter pathways, including:
5-HT1A receptor modulation: Regulates mood, anxiety, and reward pathways, addressing psychological aspects of opioid withdrawal.
Mu-opioid receptor (“MOP”) interaction: Provides partial modulation of opioid effects, potentially reducing cravings and withdrawal symptoms without reinforcing addiction.
Orexin-2 receptor (“OX2R”) partial agonist: Aids in restoring sleep-wake cycles and enhancing cognitive stability, which are significantly disrupted during opioid withdrawal.
Scientific RationaleFentanyl, a synthetic opioid that is up to 50 times more potent than heroin, has driven a global health crisis due to its high abuse potential and severe withdrawal symptoms. Traditional treatments, such as methadone and buprenorphine, often come with limitations, including risk of dependence and regulatory hurdles.
Mazindol ER offers a potential non-opioid alternative, addressing the underlying neurochemical imbalances associated with fentanyl addiction while supporting recovery through its multimodal action on neurotransmitter systems. The sustained-release formulation provides a long-acting therapeutic effect, improving patient compliance and minimizing withdrawal-related disruptions.
Mechanism of Action of Mazindol ERMazindol’s unique pharmacodynamic properties position it as a promising candidate for opioid dependence treatment. Its mechanisms include:
Inhibition of dopamine and norepinephrine transporters, restoring neurochemical balance and reducing cravings.
5-HT1A receptor modulation, potentially alleviating anxiety and depressive symptoms associated with withdrawal.
MOP agonist activity, which may help mitigate opioid withdrawal symptoms while preventing full opioid reinforcement.
Partial OX2R agonist activity, aiding in circadian rhythm regulation and reducing the impact of opioid-induced sleep disturbances.
Preclinical Study Objectives and Next Steps
The preclinical study, designated Study KO-943, will focus on:
Evaluating the safety and efficacy of Mazindol ER in fentanyl dependence models.
Assessing pharmacokinetics and pharmacodynamics in opioid-exposed subjects.
Exploring the impact of Mazindol ER on craving reduction, withdrawal mitigation, and cognitive performance.
The study is expected to be completed within 12-18 months. Upon successful results, NLS will potentially seek regulatory pathways to advance to clinical development.
“We believe that Mazindol ER could offer a paradigm shift in opioid addiction treatment,” added Dr. Konofal, M.D./PhD, Chief Scientific Officer of NLSP. “Our stepwise development plan prioritizes early-stage investment to generate critical data that will pave the way for larger-scale studies and potential commercialization opportunities.”
Existing Patent Portfolio
NLS Pharmaceutics has secured several patents supporting the development of Mazindol ER:
United States Patent No. 11,207,271: Covers oral formulations containing immediate-release and sustained-release layers of mazindol and their use in treating attention deficit disorders (“ADHD”) as well as sleep disorders.
United States Patent No. 11,596,622: Granted for the use of Mazindol ER in the treatment of heroin dependence, providing a new therapeutic strategy for opioid use disorder.
These patents strengthen the Company’s intellectual property position and support the ongoing development of Mazindol ER for various indications.
Future Outlook
NLS aims to utilize initial findings to expanded research and potential commercialization of Mazindol ER in the treatment of fentanyl dependence. Other pipeline candidates include:
NLS-4 (Lauflumide): A wake-promoting agent with applications in military and emergency response.
NLS-11 (Benedin): A circadian rhythm modulator with potential applications for space missions and the ultra-rare Kleine-Levin Syndrome (KLS).
NLS-3 (Levophacetoperane SR): A novel treatment for ADHD and Autism Spectrum Disorders, with potential pro-drug development.
Lead Asset: Mazindol ER
Mazindol ER is a patented and proprietary formulation of the active compound mazindol, and are designed for once-daily dosing. Mazindol has a well-established safety record from its long history of clinical use in the United States and in Europe when the drug was approved in an immediate release formulation for the management of obesity. Mazindol was marketed for nearly 30 years under the trade name Sanorex® before being voluntarily withdrawn from the market, and the drug is no longer available nor marketed in these regions. During its time on the market, mazindol was also widely used off-label and prescribed under compassionate use for the treatment of narcolepsy for several decades. Use in these compassionate use programs has yielded evidence of positive efficacy in patents suffering from the symptoms of narcolepsy including patients that were refractory to approved treatments for the disorder. Additionally, these same programs, a retrospective analysis of investigator sponsored studies, and NLS’s own trial evaluating Mazindol ER in patients with ADHD provide evidence of the drug’s favorable safety profile at doses that yielded efficacy signals.
We believe that our lead product candidate, Mazindol ER, offers a differentiated profile with clincally meaningful advantages over current treatment options for narcolepsy for the following reasons:
Mechanism of action
If approved, Mazindol ER would be the only partial orexin 2 receptor agonist as well as the only triple monoamine reuptake inhibitor approved by the FDA for the treatment of narcolepsy. Narcolepsy is caused by a profound loss of orexin producing neurons. A partial orexin 2 receptor agonist may help to replace missing endogenous orexin peptide, addressing the underlying cause of the disease. In addition, the drug’s action as a triple monoamine reuptake inhibitor can further reduce disease specific symptoms, offering patients a treatment option that may address the two primary symptoms of narcolepsy – excessive daytime sleepiness (EDS) and cataplexy attacks – in a convenient once-daily oral tablet.
Low potential for abuse, misuse, and diversion.
Mazindol is currently classified by the DEA as a Schedule IV controlled substance . The DEA defines Schedule IV controlled substances as those “with a low potential for abuse and a low risk of dependence”. Unlike Xyrem® (sodium oxybate), the top-selling treatment for narcolepsy in the United States deemed to have a high potential for abuse/misuse (Schedule III), mazindol was never required by the FDA to have a risk evaluation and mitigation strategy (REMS) program in place to manage known or potential serious risks associated with its use.
Quilience® has potential to be administered as a monotherapy.
Narcolepsy is a difficult disorder to manage and even with available treatments, the majority of narcolepsy patients often require multiple medications to treat their symptoms. According to the current treatment guidelines (initially published in 2007) of the American Academy of Sleep Medicine, or AASM, medications for narcolepsy, at best, provide only moderate improvement in narcolepsy symptoms, and their respective side effects may limit their use. The AASM specifically highlights that future investigations should be directed toward more effective and better tolerated therapies for treatment. The Voice of the Patient report from the FDA’s patient-focused drug development initiative, published in 2014, concluded that, based on the overall benefit-risk assessment of current medications, there is a continued need for additional effective and tolerable treatment options for patients with narcolepsy. A retrospective analysis (Nittur et.al, Sleep Med. 2013 Jan;14(1):30-6) showed that mazindol has a long-term, favorable benefit/risk ratio in 60% of drug-resistant patients with hypersomnia, including a clear benefit on the two primary symptoms of narcolepsy–EDS and cataplexy.
Mazindol ER is being developed as a once-daily oral tablet administered in the morning upon wakening.
Patients have identified a need for treatment options that are easier to take, dosed less frequently, do not disrupt nighttime sleeping, and provide full day coverage of symptoms. We believe that once-daily dosing with Mazindol ER may address this need and may help improve patient compliance and adherence with treatment. Mazindol ER utilizes our patented and proprietary extended-release (ER) formulation and is being designed to optimize its pharmacokinetic and pharmacodynamic properties with a rapid onset of action and prolonged controlled therapeutic effect, allowing for a daily oral dose that effectively provides consistent and long-acting symptom control to uniquely meet the needs of patients.
Relationship Between Narcolepsy and ADHD
Narcolepsy and psychiatric disorders have a significant but under-recognized relationship in which the two may coexist. However, narcolepsy is frequently misdiagnosed initially as a psychiatric condition, contributing to protracted times for accurate diagnosis and treatment. Narcolepsy is a disabling neurological condition that carries a high risk for the development of social and occupational dysfunction. Deterioration in function associated with narcolepsy may lead to the secondary development of psychiatric symptoms and inversely, the development of psychiatric symptoms can lead to a deterioration in function and quality of life. The overlap in treatments may further enhance the difficulty to distinguish between diagnoses.
ADHD is the most common neurobehavioral disorder characterized by symptoms of inattention, impulsivity and hyperactivity with an estimated prevalence rate of approximately 4-12% worldwide, as reported by the paper, “Understanding Attention Deficit/Hyperactivity Disorder From Childhood to Adulthood,” by Drs. Timothy E. Wilens and Thomas J. Spencer.
On the surface, ADHD may appear to be the opposite of narcolepsy; however, there may actually be significant clinical similarities between the two disorders. Cumulative data on sleep problems in children and adolescents with ADHD have shown that children with ADHD have had a higher rate of restless sleep, impaired sleep, and daytime sleepiness than children without ADHD. However, it is unclear whether EDS in ADHD is due to nocturnal sleep disturbances or primary vigilance disorders because shorter sleep onset latency is assessed in ADHD patients by the Multiple Sleep Latency Test, rather than in the control group irrespective of the presence/absence of sleep disturbances.
Alternatively, problems with sleep may represent an intrinsic component of ADHD. The presence of ADHD symptoms in children and adolescents with narcolepsy has been found to be about two-fold higher than in the general control population. Adults with narcolepsy have been found to have a much greater likelihood of having a diagnosis of ADHD in childhood compared to the general control population. Hyperactivity seen in ADHD may, in fact, be a compensatory response for individuals who are under-aroused or sleepy, and ADHD symptoms contribute to poor quality of life and increased frequency of depressive symptoms, similar to narcolepsy. To the best of our knowledge, almost all of the treatments used in ADHD have mechanistic overlap with treatments used in narcolepsy for EDS, and researchers suggest that the symptoms of EDS, fatigue, and sleep fragmentation may be the cause for ADHD symptoms, which is consistent with similar findings in other hypersomnia disorders.
AstroRx, the medical product for ALS treatment that is being researched by Kadimastem, the company NLSP has signed a binding merger agreement with, was granted Orphan drug status by the FDA. This status grants the company that manufactures the drug marketing exclusivity for 7 years from the date of receipt of marketing approval of the drug. The recognition of orphan drug status also enables accelerated examination and response paths from the FDA and other regulatory authorities.
Additionally, Kadimastem is focused on the generation and manufacturing of pancreatic insulin secreting islets (IsletRx) from embryonic stem cells for the treatment of insulin dependent diabetes such as Type 1 Diabetes. This program is in pre-clinical phase and they are moving fast down the regulatory path to start human trials. The number of patients with diabetes was estimated to be over 366 million worldwide in 2011 and is projected to be more than 552 million in 2030. The American Diabetes Association (ADA) estimated the total annual costs of diabetes to be US$223.5 billion (in the US alone). The global cost is estimated to be US$465 billion annually and will grow to about US$510 billion by 2030.
MANAGEMENT TEAM
AlexZwyer, MBA
Chief Executive Officer & Co-Founder
A co-founder of the company with extensive operational, C-level pharmaceutical experience as well as a serial entrepreneur and strong leader with a proven track-record.
Alex Zwyer has served as our Chief Executive Officer and as a Director since our incorporation in August 2015. Mr. Zwyer has over 25 years of international business experience of which more than 10 years as a C-level executive in the pharma/biotech field. In 2007, prior to, and until founding NLS in 2015, Mr. Zwyer founded a startup in the high-end luxury food sector, and served as its chief executive officer until 2015 when he successfully sold the company. From 1991 and until 2007, Mr. Zwyer served in various positions with Viforpharma AG (SWX: VIFN) (then known as Vifor (International) Inc.), most notably serving as Executive Vice President (chief operating officer), leading the company’s global regulatory affairs, medical affairs, sales and marketing as well as business development teams. Mr. Zwyer speaks seven languages fluently. Mr. Zwyer holds a B.B.A. in business administration from Oekral, Zurich, Switzerland and an executive M.B.A. from GSBA/Lorange Institute of Business, Zurich, Switzerland and an M.B.A. from University at Albany SUNY.
GeorgeApostol, MD MS
CMO & Global Head R&D
Dr. Apostol’s career spans more than 20 years in pharma industry and consists of a broad drug development expertise across early, middle and late phases of development at the global R&D organizations of Eli Lilly, Pfizer, Abbott, Novartis, Shire and Endo.
His main areas of capability include orphan diseases in CNS, in particular Fragile X Syndrome, Alagille Syndrome, but also ADHD, anxiety, depression, migraine, Parkinson’s and schizophrenia. He has built multiple drug development teams both in the US and Europe, several receiving distinguished corporate R&D awards and achieving multiple regulatory approvals in US, EU and Japan. He holds a MD degree from the Carol Davila Medical School in Romania and a MS in Clinical Research from University of Minnesota.
EricKonofal, MD, PhD
Chief Scientific Officer and Co-Founder
A co-founder of the company with a deep knowledge and experience in clinical and scientific research. He is also a drug-hunter & pipeline developer for sleep disorders as ADHD.
Dr. Konofal is a primary clinical and international scientific researcher, and is an accomplished drug hunter and drug pipeline developer. He is a senior medical consultant for the Pediatric Sleep Disorders Center at Robert-Debre University of Paris (APHP). Dr. Konofal served as Principal Clinical Investigator at the Clinical Pharmacology & Pharmacogenetic Department at Robert-Debre University of Paris. His research has focused on brain- and iron-dopamine interactions in subjects with neurological sleep disorders (RLS, PLMS), and ADHD. Additionally, Dr. Konofal served as a consultant at the sleep disorder center of Pitié-Salpêtrière University Hospital Group (APHP), specializing in ADHD, RLS, PLMS and CDH. He initiated previous studies based on iron and its role in the pathophysiology of ADHD, and has conducted extensive research on the relationship between the brain and iron.
He launched a clinical trial on the efficacy of mazindol in children with ADHD (clinicaltrials.gov identifier: NCT00508677) and obtained the U.S. patent for mazindol in the treatment of ADHD. Dr. Konofal wrote the scientific rationale for Nolazol® and discovered the pharmacological profile of mazindol and its orexin-2 receptor binding properties. He has authored over 70 peer-reviewed publications in the area of sleep disorders and other CNS diseases.
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF FIVE THOUSAND TWO HUNDRED FIFTY USD BY LFG EQUITIES CORP FOR A ONE DAY NLSP AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
Advancing the Future of Cancer Treatment with Next-Generation Therapies
Ropidoxuridine (IPdR) is a lead candidate radiation sensitizer designed for use in combination with radiation therapy (RT) to treat brain tumors (glioblastoma), a deadly malignancy of the brain with no known cure
Shuttle Pharmaceuticals has received Orphan Drug Designation from the FDA for IPdR, providing potential marketing exclusivity upon first FDA approval for the treatment of the disease
Today’s profile shot up early on and exploded double digits before coming back down. We are certainly operating in volatile markets.
Let’s switch it up a bit today and give you tomorrow’s ticker ahead of time, while the after hours markets are still open.
Put SHPH on your screen right away and watch it immediately as we head into the last session of the week.
Founded in 2012 by faculty members of Georgetown University Medical Center, Shuttle Pharma is a discovery and development-stage specialty pharmaceutical company focused on enhancing outcomes for cancer patients undergoing radiation therapy (RT).
Dedicated to advancing therapies that maximize RT effectiveness while minimizing side effects, the company seeks to improve cancer treatment strategies. By developing radiation sensitizers, the goal is to increase cancer cure rates, extend patient survival, and enhance quality of life—whether used as a primary treatment or in combination with surgery, chemotherapy, and immunotherapy.
Shuttle Pharmaceuticals is dedicated to pioneering the next generation of radiation oncology treatments, aiming to transform cancer care. Achieving this goal requires innovation, expertise, and an unwavering commitment to scientific progress.
Through strategic collaborations and cutting-edge research, efforts are focused on pushing the boundaries of cancer treatment. By enhancing the effectiveness of radiation therapy, the mission is to improve patient outcomes, extend survival, and offer new hope to millions impacted by cancer worldwide.
Top Reasons to Have SHPH on Your Radar
Expanding Oncology Market: The global oncology market is projected to reach $903.81 billion by 2034,* presenting a massive growth opportunity for innovative cancer therapies.
Lead Candidate with Strong Potential: Ropidoxuridine (IPdR), a radiation sensitizer, seeks to enhance the effectiveness of radiation therapy for aggressive cancers like glioblastoma.
Orphan Drug Designation: IPdR has received FDA Orphan Drug Designation, which may provide market exclusivity upon approval, increasing its commercial potential.
04Pipeline of Therapeutic Candidates : In addition to Ropidoxuridine, three lead candidates are in development for the treatment of solid tumors, including breast cancer, lung cancer, and multiple myeloma.
SP-2-225: A selective HDAC6 inhibitor, integral for antigen presentation by macrophages to T-lymphocytes.
SP-1-303: A Class I HDAC inhibitor with preferential efficacy against ER-positive cancers.
SP-1-161: A lead candidate that activates the ATM gene, which plays a critical role in DNA damage response and repair.
Growing Radiation Therapy Market: With 800,000 U.S. cancer patients receiving RT annually, and the global radiation therapy market expected to reach $12.93 billion by 2034,* demand for radiation sensitizers is increasing.
Diagnostics Expansion (PSMA-B Ligand, PC-Rad Test): SHPH is advancing next-generation diagnostics, including PSMA-B Ligand for prostate cancer imaging and PC-Rad Test, a novel diagnostic tool for precision radiation therapy.
Debt Level Advantage: SHPH has more cash than its total debt, strengthening its financial position and reducing risks for investors.
Strategic Partnerships & Collaborations: Partnering with Georgetown University Medical Center, UNC Medical Center, UVA Cancer Center, John Theurer Cancer Center at Hackensack University Medical Center, Allegheny Health Network Cancer Institute, and Miami Cancer Institute to advance clinical trials and research.
Positioned for Growth: The company appears well-positioned to capitalize on increasing demand for radiation sensitizers and advanced cancer treatments.
Potential First-Mover Advantage: As a company focused on improving radiation therapy outcomes, SHPH may secure an early lead in a growing and underserved market segment.
The Growing Cancer Burden and the Critical Need for Advanced Therapies
Cancer remains a major global challenge, with 20 million new cases and 9.7 million deaths recorded in 2022. One in five people develop cancer in their lifetime, and survival rates vary significantly. Prostate cancer, the second most diagnosed cancer among men, caused 396,000 deaths in 2022, with cases expected to rise to 2.4 million annually by 2040 *. This growing burden highlights the urgent need for improved treatments.
Rising Demand for Radiotherapy and Sensitizers
Radiotherapy is a key cancer treatment, with an estimated 10 million new patients needing it in 2022. By 2050, this number could rise to over 21 million . In the U.S., 800,000 cancer patients receive radiotherapy annually, half with curative intent. The demand for radiation sensitizers is expected to grow by over 22% in the next five years, creating a significant market for innovations that enhance treatment outcomes.
The Urgent Need for Better Glioblastoma Treatments
Glioblastoma (GBM), the most aggressive brain cancer, affects 3.19 per 100,000 people globally. Standard treatments—surgery, radiotherapy, and chemotherapy—face high recurrence rates, leading to poor patient outcomes. New approaches are essential to improve survival and quality of life.
Advancing Innovation in Cancer Care
With rising cancer cases and treatment limitations, the need for effective therapies is greater than ever. Radiation sensitizers present an opportunity to enhance radiotherapy’s impact, improve survival rates, and address treatment resistance, shaping the future of cancer care.
Therapeutics
Ropidoxuridine
Ropidoxuridine (IPdR) is our lead candidate radiation sensitizer for use in combination with radiation therapy (RT) to treat brain tumors (glioblastoma), a deadly malignancy of the brain with no known cure.
We have received Orphan Drug Designation from the FDA for IPdR, providing potential marketing exclusivity upon first FDA approval for treatment of the disease.
Ropidoxuridine (IPdR) is an orally available halogenated pyrimidine with strong cancer radiation sensitizing properties. Halogenated pyrimidines are incorporated into DNA by rapidly growing cancer cells and the cells become more sensitive to the effects of RT. The mechanisms underlying our candidate agents have been attributed to incorporation of IUdR, a metabolite of IPdR, into DNA, yielding reactive uracil free radicals that cause lethal DNA double strand breaks following radiation exposure.
HDAC Inhibitors
Shuttle Pharma’s HDAC inhibitors target cancer cell growth while sparing normal cells, regulating gene expression to restore tumor suppressor function. With over 20 patents, three lead candidates focus on treating solid tumors, including breast and lung cancer. These molecules enhance radiation sensitization, immune response activation, and precision oncology advancements.
Diagnostics
PSMA-B Ligand
PSMA-B Ligand is a novel boron-containing molecule designed for prostate cancer diagnosis and therapy. With strong PSMA binding, it aims to enhance proton radiation therapy and serves as a PET diagnostic and targeted treatment. Preclinical studies and a research partnership with UCSF aim to advance its development as a theranostic solution.
PC-Rad Test
The PC-Rad Test aims to address the unmet need for a predictive, minimally invasive blood test to assess prostate cancer patients’ responses to radiation therapy. Through licensed IP from Georgetown University, this biomarker program seeks to personalize treatment decisions, improve outcomes, and enhance patient-clinician decision-making in prostate cancer care.
Strategic Agreements
We have developed important strategic agreements and contractual relationships with academic institutions for access to resources such as intellectual property, core facilities and contracting relationships. Our relationships have included:
University of California, San Francisco (UCSF)
We entered into a sponsored research agreement with the University of California, San Francisco (UCSF) to advance pre-clinical development of Shuttle Diagnostics, Inc.’s (a wholly-owned subsidiary of Shuttle Pharma) ligand to the prostate-specific membrane antigen (PSMA) as a potential diagnostic and therapeutic, or theranostic, molecule. UCSF researchers, led by principal investigator, Robert Flavell, M.D., PhD., will aim to develop radiosynthetic methods for producing [18F]FPA-ACUPA probe; investigate cellular binding properties of [18F]FPA-ACUPA in PCa cell lines; and investigate the diagnostic potential of the probe across various PCa phenotypes. Shuttle Pharma has an exclusive license to the PSMA-B intellectual property and has filed a patent application with the US Patent and Trademark Office.
Georgetown University
Georgetown University is an internationally recognized educational and research university engaged in the discovery and development of new cancer diagnostics and therapeutics through the programs of the Lombardi Comprehensive Cancer Center. Shuttle Pharmaceuticals subcontracted clinical aspects of SBIR funded research to establish cancer cell lines from African-American patients and to develop predictive biomarkers for patient sensitivity to radiation late-effects.
Brown University
We have received an SBIR contract from the NIH to fund a Phase I clinical trial in collaboration with Brown University at the Lifespan/Rhode Island Hospital to determine the maximum tolerated dose in patients with advanced gastrointestinal cancers. In connection with the trial, NCI approved the Phase I clinical protocol and provided drug and clinical data management support to Rhode Island Hospital. The Phase I clinical trial has been completed and the results support advancing Ropidoxuridine to Phase II clinical trials of brain tumors, sarcomas and other tumors.
University of Virginia
The University of Virginia is an internationally recognized educational and research university engaged in the discovery and development of new cancer therapeutics and has developed the “Atomic Radiation” intellectual property. Shuttle Pharmaceuticals’ scientists collaborate with scientists at the University of Virginia to sensitizers for use with proton radiation therapy.
George Washington Cancer Center
Collaborations between the Villagra lab at George Washington University and the Shuttle Pharmaceuticals’ lab resulted in a joint presentation at the October 2020 AACR Conference of research addressing: “Immune-mediated Tumor Growth Inhibition by Selective HDAC6 Inhibitor SP-2-225.” Dr. Villagra has served as a Scientific Advisor to Shuttle Pharmaceuticals with expertise in cellular signaling pathways, epigenetics and immunology since 2017. We also have a material transfer agreement for testing HDAC inhibitor effects in immune model systems
TCG GreenChem
TCG GreenChem Inc. is a sister company of TCG Lifesciences Pvt. Ltd. Both are a part of the TCG Group based in New York, NY and together a leading global Custom Research and Manufacturing Services (CRAMS) company for drug discovery, development and commercialization. They have a presence in the United States, India, and Japan. TCG GreenChem Founder and Chief Executive Officer, Chris Senanayake, PhD along with Executive Vice President and Global Head of Research and Development, Executive Vice President and Global Head of Research and Development joined Shuttle’s leadership team in 2020 to manufacture drug product for use in proposed clinical trials.
Mr. Cooper has more than 27 years of experience in management and finance, having worked in the oil and gas, telecommunications and technology industries. In addition to his appointment as Interim Co-CEO of the Shuttle Pharma, Mr. Cooper also serves as President, CEO and Founder of First Towers & Fiber Corp., a telecommunications infrastructure company with operations in Latin America, positions he has held since 2017. From 2010 until 2017, Mr. Cooper served as President and CEO of Aroway Energy, Inc., a Vancouver, British Columbia-based oil and gas company, where he was responsible for overseeing day to day operations, financial reporting, and oversaw acquisitions and debt and equity financing. From 1998 until 2010, Mr. Cooper served as a Corporate Consultant to various companies in the technology and resources sectors, oversaw restricting activities for several distressed public companies, and was responsible for raising more than $100 million in debt and equity for his clients. Mr. Cooper received his MBA from Dowling College in 1995 and his BBA in Business Administration from Hofstra University.
Anatoly Dritschilo, MD
Chief Scientific Officer & Chairman
Dr. Dritschilo is a Company co-founder and has served as Chairman of the board of directors since December 2012. Dr. Dritschilo is an American Board of Radiology certified radiation oncologist with clinical experience treating cancer patients, directing basic science and clinical research projects and serving in administrative capacities as Department Chair at Georgetown University School of Medicine; Chief of Radiation Oncology at MedStar-Georgetown University Hospital; Medical Director of Georgetown University Hospital; and Interim Director of the NCI-funded Lombardi Comprehensive Cancer Center. He has also served on the boards of directors of MedStar-Georgetown University Hospital, the National Capital Rehabilitation Hospital and the MedStar Health Research Institute. His biotech experience includes co-founding Oncomed, Inc. and service as a member of the board of directors of Neopharm, Inc. His 250+ scientific publications and 20+ issued patents have earned him election as a Fellow of the National Academy of Inventors. Dr. Dritschilo holds a Bachelor of Science (BS) degree in Chemical Engineering from the University of Pennsylvania, a Master’s Degree (MS) from the New Jersey Institute of Technology, a medical degree (MD) from the College of Medicine of New Jersey and completed residency training from the Harvard, Joint Center for Radiation Therapy.
Timothy Lorber, CPA
Chief Financial Officer
Mr. Lorber is a CPA with more than 40 years of professional finance experience, including 15 years with Legg Mason, Inc. (“Legg Mason”), one of the world’s larger public global asset management firms where he served as a Managing Director and Chief Accounting Officer until its sale in 2020. More recently, Mr. Lorber has served in leadership roles with several privately held businesses, overseeing finance, IT and HR functions. Prior to Legg Mason, Mr. Lorber served as Internal Audit Director of Freddie Mac and has also worked for several international public accounting firms.
Michael Vander Hoek, MHSA
Vice President, Regulatory
Mr. Vander Hoek serves as the Company’s Vice President, Regulatory. Previously he also served as the Company’s Chief Financial Officer, Prior to Mr. Tim Lorber joining the Company. Mr. Vander Hoek’s experience includes service as Director, Finance and Business Development at Georgetown Lombardi Comprehensive Cancer Center (“LCCC”), where he directed a five-year $221.9 million institutional commitment for cancer center research under an NCI-approved cancer consortium arrangement. His responsibilities included recruitment of scientists and senior leaders to address the Cancer Center’s mission. Previously, Mr. Vander Hoek served as Associate Director, Administration, at Georgetown’s LCCC, where he was directly responsible for t administrative operations and management of $216.9 million in institutional commitments to LCCC from Medstar Health, John Theurer Cancer Center (“JTCC”), and Georgetown University. Mr. Vander Hoek implemented an enterprise-wide clinical trial management system for Georgetown University and Medstar Health. Mr. Vander Hoek also served as the LCCC’s Chief Financial Officer negotiated research served as Vice-Chair, Planning and Administration, at MedStar Georgetown University Hospital. His financial management experience in publicly held companies includes Director of Managed Care Reimbursement for Critical Care America and Regional Controller for Laboratory Corporation of America (LabCorp) Mr. Vander Hoek holds a Master’s in Health Services Administration from George Washington University and a Bachelor of Arts in Biology and Psychology from Hope College.
Peter Dritschilo, MBA
President & COO
Mr. Dritschilo has served as our President and Chief Operating Officer since Shuttle Pharmaceuticals was formed in December 2012. He also served as our Chief Financial Officer until 2019. Mr. Dritschilo has more than 25 years of business management experience in medical services and cancer treatment. He has held administrative positions with Medstar-Rad America Georgetown University, Prince William Hospital/ Fauquier Hospital Cancer Center and Inova Health System’s Schar Cancer Institute. Mr. Dritschilo graduated from Georgetown University and received his MBA from George Washington University.
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF EIGHT THOUSAND TWO HUNDRED FIFTY USD BY SIDEWAYS FREQUENCY LLC FOR A ONE DAY SHPH AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
Avalon GloboCare and YOOV, a Leading Business AI Automation Solutions Provider, Enter into Merger Agreement – YOOV Achieves 59.1% Annual Revenue Growth, Reporting Unaudited Revenue of $45.7 Million
Avalon GloboCare Partners with Pounds Transformation Clinics to Unveil the KetoAir BrAce 4 Impact Challenge Series ALBT Just Had a Significant Reverse Split Months Ago, Drastically Reducing the Float to Under 1M
These markets have been extremely volatile the past week but there have been some fast moving opportunities that have paid off.
Wednesday’s profile was another fast mover that showed triple digit gains at one point before coming back down to earth. This one was just over a buck in the premarket before exploding to over 4 dollars and opening at 2.40 during the session.
We have another potential fast mover on deck for Thursdays session.
Put ALBT on your radar and get ready for the open.
This one went through a 15-1 reverse split back in October, reducing the float on this to under 1M according to FINVIZ.
You are going to want to keep a close eye on this one heading into the bell.
Avalon GloboCare Corp. (NASDAQ: ALBT) is a commercial-stage company dedicated to developing and delivering precision diagnostic consumer products. Avalon is currently marketing the Keto Air breathalyzer device and plans to develop additional diagnostic uses of the breathalyzer technology. In addition, the company owns and operates commercial real estate.
Avalon GloboCare and YOOV, a Leading Business AI Automation Solutions Provider, Enter into Merger Agreement
YOOV Achieves 59.1% Annual Revenue Growth, Reporting Unaudited Revenue of $45.7 Million with Net Income of $3.4 Million for Calendar Year 2024, Versus Unaudited Revenue of $28.7 Million with Net Loss of $2.4 Million for Calendar Year 2023
Upon Consummation of the Merger, Pending Nasdaq Approval, the New Combined Company is Expected to Trade Under the Nasdaq Symbol “YOOV”
FREEHOLD, N.J., March 10, 2025 (GLOBE NEWSWIRE) — Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a commercial-stage company dedicated to developing and delivering precision diagnostic consumer products, announced today that it has entered into a definitive merger agreement with YOOV Group Holding Limited (“YOOV”), a leading provider of business artificial intelligence (“AI”) automation solutions. Under the agreement, YOOV will merge with and into Avalon (the “Proposed Merger”). The combined company is expected to operate under the name YOOV, Inc. and expected to continue trading on The Nasdaq Capital Market under the symbol “YOOV”. The transaction is expected to close in the third quarter of 2025. The completion of the Proposed Merger is subject to several conditions, including the approval of the stockholders of Avalon.
YOOV’s highly advanced AIaaS (Artificial Intelligence as a Service) platform is transforming enterprise workflow management, communication, and operational efficiency. The company’s proprietary AIaaS platform makes AI accessible and empowers businesses of all sizes to streamline processes, optimize resources, and improve productivity through intelligent automation. With a strong emphasis on scalability and flexibility, YOOV enables businesses to adapt their platforms to their specific needs, thereby maximizing the impact of automation across various sectors.
Driven by increasing demand for AI-powered business automation, YOOV had unaudited revenue of $45.7 million and net income of $3.4 million for the calendar year ended December 31, 2024, compared to unaudited revenue of $28.7 million and a net loss of $2.4 million for the calendar year ended December 31, 2023. In addition, YOOV had unaudited revenue of $29.6 million and net income of $1.3 million for the fiscal year ended March 31, 2024 compared to unaudited revenue of $21.5 million and a net loss of ($527,403), for the fiscal year ended March 31, 2023.
Dr. David Jin, M.D., Ph.D., CEO of Avalon GloboCare, stated, “We believe this transaction is in the best interest of our shareholders, providing a unique opportunity to unlock value and participate in the future of AI-driven automation. We believe that YOOV’s advanced AI technology, strong market presence, and rapid growth trajectory represent a compelling market opportunity. We believe this merger has the potential to drive innovation, scalability, and long-term shareholder value.”
Phil Wong, Co-Founder and CEO of YOOV, commented, “We believe this merger will provide us with a foundation to accelerate our growth, extend our impact across industries, and strengthen our ability to drive innovation. We look forward to leveraging this opportunity to create lasting value for our respective businesses and shareholders.”
About the Proposed Transaction, Management & Organization
Under the terms of the merger agreement, subject to stockholder approval, on a pro forma basis, post-merger Avalon equityholders are expected to collectively own between approximately 2.5% to 2.2% and YOOV equityholders are expected to collectively own between approximately 97.5% and 97.8% of the common stock of the combined company on a pro forma basis, depending on the market price of Avalon’s common stock at the time of the completion of the merger.
The merger agreement has been approved by the boards of directors of both companies and is subject to stockholder approval of both companies and other customary closing conditions. The proposed merger is expected to close in the third quarter of 2025.
Following the merger, Phil Wong will become Chairman, Chief Executive Officer, and President. The merger agreement provides that the board of directors of the combined company will be composed of seven members, with five members initially designated by YOOV and two members initially designated by Avalon.
Roth Capital Partners acted as the exclusive financial advisor to Avalon in connection with the merger.
For further information regarding the terms and conditions contained in the Merger Agreement, please see Avalon’s current report on Form 8-K, which was filed with the U.S. Securities and Exchange Commission in connection with the Proposed Merger.
The financial information contained in this press release is unaudited and is based on preliminary internal data of YOOV. In addition, the information for the fiscal years ended March 31, 2023, and March 31, 2024, is subject to completion of YOOV’s audit. This financial information is subject to change and may differ from the final audited financial statements. Avalon and YOOV do not undertake any obligation to update this information, except as required by applicable law. Readers are cautioned not to place undue reliance on this unaudited financial information, as it may not provide a complete or accurate picture of YOOV’s financial condition or results of operations.
About YOOV Group Holding
YOOV is an Artificial Intelligence (AI) as a Service (AIaaS) platform specializing in intelligent business automation, integrating AI, process and data into one platform to make business operations easy, efficient, and effortless. YOOV empowers businesses of all sizes to use AI without the need for extensive resources or technical expertise. By seamlessly integrating robotic process automation (RPA) with advanced AI capabilities, YOOV delivers versatile solutions tailored to meet the diverse needs of various industries. Over the years, YOOV has been growing rapidly with a strong global presence.
Beyond its core AI automation solutions, YOOV extends its offerings into financial and insurance services through its subsidiaries, YOOV Capital Limited and YOOV Insurance Services Limited. These subsidiaries leverage YOOV’s commercial data insights to provide credit evaluation and insurance brokerage services, further enhancing the YOOV ecosystem and delivering added value to clients.
Avalon GloboCare Partners with Pounds Transformation Clinics to Unveil the KetoAir BrAce 4 Impact Challenge Series
KetoAir Now In Stock at All Three Pounds Transformation Clinics in Connecticut
FREEHOLD, N.J., April 01, 2025 (GLOBE NEWSWIRE) — Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a commercial-stage company dedicated to developing and delivering precision diagnostic consumer products, today announced that it has partnered with Pounds Transformation Clinics, led by Dr. Charles Cavo, a member of the Zero to Keto Affiliate Marketing Program, to launch the “BrAce 4 Impact Challenge Series.” This new collaboration has already debuted its inaugural challenge in conjunction with Pounds Transformation’s 4-week Diet Challenge, incorporating KetoAir™ breathalyzer devices as a motivational tool. KetoAir™ devices are now available on consignment at all three Pounds Transformation locations in West Hartford Center, Southington, and Glastonbury, Connecticut.
Following the successful conclusion of the 4-week BrAce 4 Impact Challenge Pilot on March 18, 2025, Pounds Transformation is kicking off the first official BrAce 4 Impact Challenge starting April 1, 2025. “I saw a patient today from the BrAce 4 Impact Challenge pilot who is doing extremely well,” said Dr. Charles Cavo. “She uses the KetoAir™ three times a day and has never experienced this level of weight loss before. Her BrAce readings remain around 12ppm, and she’s never felt better. The KetoAir™ keeps her ‘honest’ and on track. With the level of results our patients are achieving with the help of the KetoAir™, it is our intent to begin new BrAce 4 Impact Challenges every six weeks,” added Dr. Cavo. To further support participants, Pounds Transformation has assigned a dedicated coach as the daily point of contact throughout the Challenge Series.
Pounds Transformation is a Connecticut-based health and wellness clinic focused on long-term weight management. Their programs address the root causes of weight gain through evidence-based interventions, ongoing support, and regular monitoring of key health markers.
KetoAir™ is a handheld breathalyzer, specifically engineered for ketogenic health management (United States FDA registration number: 3026284320). KetoAir™ measures an individual’s breath acetone concentration (BrAce), a ketone body that rises as fat oxidation increases. By leveraging the nano-sensor-based technology, the KetoAir™ breathalyzer is designed to assess the ketosis status of its individual user and is accessible on both the Apple App Store and Google Play Store.
“We are very pleased with the expansion of our partnership with Pounds Transformation clinics,” said David Jin, M.D., Ph.D., CEO of Avalon GloboCare. “It’s rewarding to see the KetoAir™ device have such a positive impact on their patient programs, supporting real-time, personalized insights that empower individuals on their wellness journey. This partnership highlights our shared commitment to delivering innovative, accessible tools that improve health outcomes and encourage long-term lifestyle changes.”
“Integrating the KetoAir™ Breathalyzer into our programs allows our patients to track their ketone levels in real time, helping them stay motivated and engaged in their daily routines,” said Dr. Charles Cavo, Co-founder of Pounds Transformation. “Many of our patients have struggled with weight loss for years. KetoAir™ provides immediate feedback that helps validate their progress, reinforce positive behavior, and improve accountability. It’s become a valuable tool in helping our patients understand their bodies and take control of their health in a sustainable way.”
Dr. David Jin, MD, PhD, a director and Chief Executive Officer of the Company and AHS. From 2009 to 2016, Dr. Jin has served as the Chief Medical Officer of BioTime, Inc. (NYSE MKT: BTX), a clinical stage regenerative medicine company with a focus on pluripotent stem cell technology. Dr. Jin also acts as a senior translational clinician-scientist at the Howard Hughes Medical Institute and the Ansary Stem Cell Center at Weill Cornell Medical College of Cornell University. Prior to his current endeavors, Dr. Jin was Chief Consultant/Advisor for various biotech/pharmaceutical companies regarding hematology, oncology, immunotherapy and stem cell-based technology development. Dr. Jin has been Principle Investigator in more than 15 pre-clinical and clinical trials, as well as author/co-author of over 80 peer-reviewed scientific abstracts, articles, reviews, and book chapters. Dr. Jin studied medicine at SUNY Downstate College of Medicine in Brooklyn, NY. He received his clinical training and subsequent faculty tenure at the New York-Presbyterian Hospital (the teaching hospital for both Cornell and Columbia Universities) in the areas of internal medicine, hematology, and clinical oncology. Dr. Jin was honored as Top Chief Medical Officer by ExecRank in 2012, as well as recognized as Leading Physicians of the World in 2015.
Meng Li
Chief Marketing Officer, Secretary
Ms. Li served on the Company’s board from October 2017 through July 2018 and was re-appointed in February 2019. Ms. Li has over 15 years of executive experience in international marketing, branding, communications, and media investment consultancy. Ms. Li served as Managing Director at Maxus/GroupM (a WPP Group company) where she was responsible for business P&L and corporate management from 2006 to 2015. Prior to joining Maxus/Group M, Ms. Li worked for Zenith Media (a Publicis Group company) from 2000 to 2006 as Senior Manager. Ms. Li received a Bachelor of Arts in International Economic Law from Dalian Maritime University in China.
Luisa Ingargiola
Chief Financial Officer
Luisa Ingargiola is the Company’s Chief Financial Officer. Ms Ingargiola has significant experience serving as Chief Financial Officer or Audit Chair for multiple NASDAQ and NYSE companies. She currently serves as Director and Audit Chair for several public companies including ElectraMeccanica (NASDAQ:SOLO), Dragonfly Energy (NASDAQ:DFLI)and Vision Marine Technolgoies (NASDAQ:VMAR)). From 2007 through 2016, Ms. Ingargiola served as the Chief Financial Officer and then Director at MagneGas Corporation (Nasdaq: MNGA). Prior to 2007, Ms. Ingargiola held various roles as Budget Director and Investment Analyst in several private companies. Ms. Ingargiola graduated in 1989 from Boston University with a Bachelor’s degree in Business Administration and a concentration in Finance. In 1996, she received her MBA in Health Administration from the University of South Florida. Ms. Ingargiola is qualified to serve as a Chief Financial Officer because of her extensive knowledge corporate governance, regulatory requirements, executive leadership and knowledge of, and experience in, financing and M&A transactions.
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SIX THOUSAND USD BY SHORE THING MEDIA LLC FOR A ONE DAY ALBT AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
The 60,000 square foot facility in Mocksville, North Carolina has the capacity to produce more than 45 million cartons of combustible tobacco products annually
VLN® is available in over 5,000 stores across 26 states
22nd Century Continues CMO Business Expansion with Additional Filtered Cigar Volume
Today’s profile was crazy. It exploded up over 100% on massive interest. We hope you had a chance to research it last night.
It ran all the way to 4.40 after closing yesterday just above 2 bucks. Not bad right?
We have another company on our radar for Tuesday’s session that you are going to want to pay attention to.
Pull up XXII immediately.
2nd Century Group, Inc. (Nasdaq: XXII) is the pioneering nicotine harm reduction company in the tobacco industry enabling smokers to take control of their nicotine consumption.
They created their flagship product, the VLN® cigarette, to give traditional cigarette smokers an authentic and familiar alternative that helps them take control of their nicotine consumption. VLN® cigarettes have 95% less nicotine than the traditional cigarette and have been proven to greatly reduce nicotine consumption. Instead of offering new ways of delivering nicotine to addicted smokers, they offer smokers the option to take control of their nicotine consumption and make informed and more productive choices, including the choice to avoid addictive levels of nicotine altogether.
Their wholly owned subsidiaries include a leading cigarette manufacturer that produces all VLN® products and provides turnkey contract manufacturing for other tobacco brands both domestically and internationally. The 60,000 square foot facility in Mocksville, North Carolina has the capacity to produce more than 45 million cartons of combustible tobacco products annually with additional space for expansion.
Their proprietary reduced nicotine tobacco blends are made possible by comprehensive and patented technologies that regulate nicotine biosynthesis activities in the tobacco plant, resulting in full flavor and high yield with 95% less nicotine. Their extensive patent portfolio has been developed to ensure we have the only low nicotine combustible cigarette in the United States and critical international markets.
Currently, VLN® is available in over 5,000 stores across 26 states, but that could be just the start.
22nd Century has announced ambitious plans to extend distribution to over 270,000 retail outlets nationwide. And no stopping there. International expansion is also on its agenda, with established partnerships in markets like South Korea, that where the demand for harm-reduction products is growing. And the infrastructure for growth is in place. XXII’s supply chain includes a stockpile of low-nicotine tobacco ready to meet demand and has the additional capacity to manufacture up to 1.4 million cartons of VLN® cigarettes—enough to generate up to $85 million in revenue. In other words, XXII isn’t just poised for success; they have the infrastructure in place to meet the increasing consumer demand for their products.
On Tuesday the company announced:
22nd Century CEO & Chairman Larry Firestone Provides Corporate Update Letter to Stockholders
Corporate Update Letter Highlights Plans to Begin Profitable Growth Phase in 2025 on Expansion of Rebranded VLN® Cigarette Products
MOCKSVILLE, N.C., April 08, 2025 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (Nasdaq: XXII), a tobacco products company that is leading the fight against nicotine by offering smokers a choice about their nicotine consumption, today issued the following letter to stockholders from Larry Firestone, the Chief Executive Officer of 22nd Century Group, Inc.:
A Letter to Our Shareholders From Larry Firestone, CEO & Chairman – 22nd Century Group
It’s been 16 months since I stepped into the role of Chairman and CEO, and I’ve never been more energized by the mission we’re driving forward together.
Before diving into this update, I want to take a moment to express my genuine appreciation to every member of our team whose vital roles help 22nd Century Group change the future of nicotine consumption. Thank you!! You are the reason we’re making real progress—and the reason that we will be successful.
I’ll walk you through a few industry shifts that are working in our favor and what’s still ahead of us to achieve greatness.
Our Industry – Tobacco
Big Tobacco for decades has dominated the industry, with a market size that is over $85 billionstrong and a single mission to keep people dependent on nicotine.
At 22nd Century, we’re flipping that script. The majority of adult smokers say they want to quit, but fewer than 10% actually can. That’s where VLN® steps in. We’re not trying to reinvent the wheel—we’re redefining it. VLN® is the only FDA-authorized cigarette that puts control back in the smoker’s hands with 95% less nicotine.
There’s one big question we keep asking: What if smokers could take control of their nicotine consumption and still enjoy a cigarette?
Nicotine dependence still drives billions in healthcare costs and keeps nearly 29 million adult smokers in a cycle they want out of. Nearly half that number, 15 million try to quit every year with less than 1 in 10 succeeding.
This is why VLN® matters. We’re not asking smokers to quit—we’re giving them the option to manage their consumption without compromise. VLN® lets smokers keep the ritual, the sensation, the satisfaction—on their own terms. Real choice. Real control.
And with the FDA proposing new lower nicotine limits, VLN® already meets this standard. No scrambling needed. While others are stuck in the approval queue, we’re in the market and ready to go.
A great example of a changing landscape is the zero- and low-proof spirits trend. A few years ago, it was niche. Now, it’s a multi-billion-dollar movement. Same deal here: even if just a fraction of adult smokers switch to VLN® for whatever reason—habit, health, or just to cut back—the VLNC (Very Low Nicotine Content) category could be worth billions. And we’re the only player leading that charge.
2024: Reset. Refocus. Relaunch
This past year was all about setting the foundation. Here’s what we have accomplished:
We went all-in on tobacco. Divested out of hemp, hops, or cannabis.
Slashed ~$18M in debt, strengthening our balance sheet
Gave VLN® a bold new look and feel with a robust go to market strategy.
Developed retail partnerships that’ll relaunch VLN® in thousands of stores across the U.S.
Vertical Integration, Strategic Expansion
Our core contract manufacturing (CMO) business is the backbone of our operations. It’s high-volume, low-margin—and absolutely essential to our success. We provide full turnkey services to secondary and tertiary tobacco brands providing manufacturing, compliance, and supply chain. They handle the brand. We handle everything else for them.
Here’s why CMO is a major strategic win:
It gives us a vertically integrated platform for our core product—we control the manufacturing, distribution, and marketing of VLN® and other proprietary products.
With new long-term, properly priced contracts, CMO provides revenue that addresses all of our overhead and provides stability to our operations.
It opens doors. We’re leveraging customer partnerships and brand equity to launch VLN® and new partner brands—growing into new channels and stores.
Starting Q2 2025, we’re hitting the market with our bold new branding, featuring:
VLN® Gold
VLN® Red
VLN® Green (Menthol)
Already in 5,000+ stores—and aiming for a growing slice of the 272,000-stores nationwide.
We’re also launching partner-branded VLN® products—a win-win. Our CMO customers get a premium, high-margin SKU and we get a fast track into new stores, new audiences, and greater awareness. Think of it like your favorite beverage offering a low-proof version: same vibe, less buzz, new category.
And that’s exactly where we’re headed: building the Very Low Nicotine Content (VLNC) category. Just like low-proof spirits carved out their space, VLN® will stand on its own shelf—with its own story.
2025 and Beyond: Time to Grow
We’ve stabilized. We’ve streamlined. And we’ve struck the match and created the spark.
This year is about scale—and profit. VLN® is our statement. Our CMO business is funding our freedom. We’ve got the strategy, team, and partnerships to finally take 22nd Century into self-sustaining territory.
We’re not just building a brand. We’re creating a whole new lane in the $85 Billion Dollar industry—and bringing smokers options with VLN®.
Thanks for being part of the journey.
Larry FirestoneChief Executive Officer
Products:
Reduced Nicotine Content (RNC) Tobacco Plants:
Very Low Nicotine (VLN) Cigarettes:
They offer cigarettes containing 95% less nicotine than conventional cigarettes, with the sole function of making it easier to reduce the number of cigarettes smoked.
FDA Authorization:
They received the first and only FDA MRTP authorization for a combustible cigarette in December 2021
22nd Century Group Reports Fourth Quarter and Full Year 2024 Financial Results
Launches 2025 Growth Strategy Leveraging Both Internal and External Brand Assets Across Multiple Categories
Announces First VLN® Partner Brands with Smoker Friendly Ready for Shipment in Q2 2025, Additional Partner VLN® Brands in Discussion
MOCKSVILLE, N.C., March 20, 2025 (GLOBE NEWSWIRE) — 22nd Century Group, Inc.(Nasdaq: XXII), a tobacco products company that is leading the fight against nicotine dependence and believes smokers should have a choice about their nicotine consumption, today announced results for the fourth quarter and year-ended December 31, 2024, and provided an update on recent business highlights.
Fourth Quarter and Full Year 2024 Financial Results (compared to Third Quarter 2024, except as noted)
All figures reported below reflect continuing operations, excluding discontinued operations related to the sale and exit of the Company’s hemp/cannabis business in late 2023.
Net revenues decreased sequentially to $4.0 million, compared to $5.9 million.
Gross profit (loss) was $(1.3) million, compared to $(0.6) million.
Operating loss increased to $4.1 million, compared to $3.4 million.
Net loss increased to $4.2 million, compared to $3.6 million.
Adjusted EBITDA loss was $3.9 million, from a loss of $3.2 million.
Ended fiscal 2024 with net debt of $3.3 million.
Recent Business Highlights
Launched new VLN® branding, ready for shipment in the second quarter 2025, including a new logo, packaging and marketing plan.
Announced first VLN® partner brand with Smoker Friendly, ready for shipment in the second quarter of 2025.
Progressed in securing additional VLN® partner brands, working toward a new reduced nicotine content product category.
Signed a new five-year expanded license and manufacturing agreement with Smoker Friendly, covering 11 existing products and eight new premium products to be launched.
Announced compliance with the FDA’s proposed new tobacco product standard for nicotine yield, which cites VLN® from 22nd Century as the only combustible cigarette on the market that currently meets the new standard of a maximum nicotine level of 0.7 mg/g in cigarettes.
“Our 2024 results demonstrate a challenging but transformative year as we worked our turnaround plan and reset almost all aspects of our business. We are starting 2025 with a new base focused on growth across all of our revenue lines. Our contract manufacturing business begins the year with profitable contracts, and we have begun the relaunch of our reduced nicotine VLN® cigarette business that will encompass both our branded VLN® products as well as private label partner VLN® products,” said Larry Firestone, Chairman and CEO. “We are excited for 2025 as this is really a new start of 22nd Century Group, Inc., and are looking forward to shaping our future around our current strategy.”
Fourth Quarter 2024 – Discussion of Product Line Net Revenues
Cigarette net revenues were $3.3 million, decreased from $4.1 million in the third quarter of 2024 reflecting a shift in overall product mix and pricing between domestic and export sales. Q4 2024 cigarette carton volumes increased to 228 thousand compared to 156 thousand in the third quarter of 2024.
Filtered cigars net revenues decreased to $0.8 million, compared to $1.7 million in the immediately preceding quarter, reflecting lower volumes as the Company completed last time buy orders under terminated contract manufacturing agreements.
Cigarillo distribution net revenues were negligible in the fourth quarter compared to $0.2 million in the preceding quarter.
VLN® cigarette net revenues were $(0.1) million in the fourth quarter, reflective of rebate and marketing incentives for product already in distribution. The Company has announced new branding for its VLN® products, which will be ready for shipment in the second quarter 2025, as well as its first partner brand VLN® products with its existing customer Smoker Friendly. Additional partner brand agreements are in progress as part of a relaunch of its VLN® reduced nicotine content products.
22nd Century Announces First Partner VLN Agreement, New VLN Availability with Smoker Friendly
Smoker Friendly Adds Both VLN and Smoker Friendly Branded VLN Reduced Nicotine Content Products to its Store Lineup
MOCKSVILLE, N.C., March 10, 2025 (GLOBE NEWSWIRE) — 22nd Century Group, Inc.(Nasdaq: XXII), a tobacco products company that is leading the fight against nicotine by offering smokers a choice about their nicotine consumption, today announced that it has signed an agreement with Smoker Friendly, one of its largest customers, to launch Smoker Friendly VLN branded reduced nicotine content cigarette products that will become the first VLN partner brand.
The introduction of Smoker Friendly VLN and 22nd Century VLN in Smoker Friendly outlets will be one of the first presentations of gold and menthol SKU’s that introduce the new VLN branding.
The addition of Smoker Friendly branded VLN and 22nd Century Group’s VLN products builds on a customer relationship of over 10 years, as does the recent addition of the Smoker Friendly Black Label style cigarette. The Companies are currently obtaining state approvals for these products and expect to begin shipping in the second quarter of 2025.
Larry Firestone, Chief Executive Officer of 22nd Century, said, “We are very excited to have Smoker Friendly adopt our first VLN partner brand and also add our newly rebranded VLN products to the Smoker Friendly product offerings in their stores. This is a foundational building block to advancing VLN in the market, and will be a staged rollout as we garner state approvals. Equally important to expanding distribution will be measuring rate of sale once VLN is on the shelf.”
Terry Gallagher, President and Chief Executive, Smoker Friendly said, “We are excited to expand our relationship and product portfolio to include the VLN lineup under our brand as well as the updated 22nd Century VLN brand products. This is an important step for the future of our partnership.”
About The Cigarette Store LLC dba Smoker Friendly
Boulder, Colorado based Smoker Friendly operates 344 stores in 13 states. The stores are a mix of tobacco stores, cigar lounges, liquor stores, and fueling locations under the names Smoker Friendly, Tobacco Depot, Smoke ‘N Go, Havana Manor, and Gasamat.
The Smoker Friendly team also manages the Smoker Friendly Authorized Dealer program. This program provides a total tobacco private label portfolio, industry expertise, a well-known name, and geographic exclusivity to tobacco retailers desiring an alternative to the contracts offered by big tobacco.
Mr. Firestone brings over 40 years of enterprise, operations, and financial management experience in both public and private companies, including tenures as CEO, CFO and COO across multiple industry sectors. Mr. Firestone most recently served as Chief Financial Officer of Oakland Manager, a privately-held purveyor of cannabis with both retail and wholesale market penetration, and as Chairman of FirePower Technology, a privately held manufacturer of ATX power supplies for the IT and instrumentation markets. In the public company sector, Mr. Firestone has served as Chief Executive Officer of Eastside Distilling, Inc. (NASDAQ: EAST), Chief Executive Officer of Qualstar Corporation (NASDAQ: QBAK), Chief Financial Officer of Advanced Energy Industries (NASDAQ: AEIS), and Chief Financial Officer of Applied Films Corporation (NASDAQ: AFCO). He has served on numerous boards, including those of Eastside Distilling, Qualstar, CVD Equipment Corporation (NASDAQ: CVD), Amtech Systems, Inc. (NASDAQ: ASYS) and HyperSpace Communications, Inc. (NYSE: HYPR). Mr. Firestone received his Bachelor of Science in Business Administration with a concentration in Accounting from Slippery Rock University of Pennsylvania.
Anthony Johnson
Director
Anthony Johnson was appointed as a member of our Board of Directors in August 2021, serving on our Scientific Advisory and Compensation Committees. Anthony is co-founder, President, and CEO of Kodikaz Therapeutic Solutions, a next-generation non-viral gene therapy company. He is also a founding partner of Buffalo Biosciences, a life science strategic business management firm that supports the evaluation and commercialization of bioscience technologies from concept to market. Previously he was president and CEO of Empire Genomics, where he transformed a concept formed at a university lab into a preeminent oncology molecular diagnostic testing enterprise. He also served as the business leader of the stem cell and regenerative medicine franchise for Thermo Fisher (Invitrogen Corporation). Anthony has leveraged his business experience and numerous board positions to mentor technology startups and entrepreneurs, spur state and local job creation, and introduce STEM curriculum into early childhood education. He is an Aspen Institute Health Innovation Fellow and member of the Aspen Global Leadership Network, and he currently serves on the board of the WNED/PBS broadcasting service of Western New York. Johnson is a founding board member of the Communities of Giving Legacy Initiative, which works to create positive change in the lives of low-income youth of color. Additionally, he serves as Michigan Street African-American Heritage Corridor Commissioner and was an Opportunities Council member for University of Buffalo. He holds an MBA from Manchester Business School, Manchester, UK, with an emphasis in international strategy, and a BA in biology from Fisk University, Nashville, TN.
Lucille S. Salhany
Director
Lucille S. Salhany was appointed as a member of our Board of Directors in September 2021, serving on the Corporate Governance and Nominating and Finance committees. Lucille is currently President and CEO of her own consulting company, JHMedia. She was also one of the founding partners of Echo Bridge Entertainment and CEO & President of LifeFX Networks, Inc. Prior to this, she served as Chairperson of the Twentieth Television division of Fox, and was appointed the first woman in history to head a major television network when she accepted the Chairmanship of Fox Broadcasting. After chairing Fox, Salhany accepted the post of Chief Executive Officer and President of United Paramount Network (UPN), launching and growing UPN to become the fifth major broadcast network. She also served on the Board of Directors for Echo Bridge Entertainment, Compaq / Hewlett-Packard, Fox, Inc., Avid Technologies, and American Media, Inc. Lucille was also a trustee of Emerson College and Lasell College, where she received Honorary Doctorates.
Andy Arno
Director
Mr. Arno previously served, until February 2023, as Vice Chairman of The Special Equities Group, a division of Dawson James Securities, Inc., plus other senior roles at investment banking firms. Prior, Mr. Arno served as Vice Chairman and Chief Marketing Officer of Unterberg Capital, LLC, an investment advisory firm that he co-founded, and as Vice Chairman and Head of Equity Capital Markets of Merriman Capital LLC, where he also served on the board of the parent company, Merriman Holdings, Inc. Mr. Arno was responsible for Capital Markets for C.E. Unterberg, Towbin, a Vice President at Lehman Brothers and in the Individual Investors Services Division of L.F. Rothschild Unterberg, Towbin in portfolio management for high-net-worth individuals. Mr. Arno is currently the Chairman of the Board of Oncocyte Corporation and also serves on the boards of directors of Smith Micro Software, Inc., Independa Inc., and Comhear Inc. Mr. Arno previously served as a director of Asterias Biotherapeutics, Inc. from August 2014 until it was acquired by Lineage Cell Therapeutics, Inc. in March 2019. Mr. Arno received a BS degree from George Washington University.
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF NINE THOUSAND TWO HUNDRED FIFTY USD BY SHORE THING MEDIA LLC FOR A ONE DAY XXII AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
SXTP Just Implemented a 1 for 5 Reverse Split, Drastically Reducing the Float
Due to a recent surge in demand for Arakoda® in the U.S. market, the Company submitted a regulatory discretion request to FDA in December 2024 to allow importation of Kodatef® (Australian-branded equivalent of Arakoda) to ensure continuous U.S. commercial supply. This was granted in February 2025, and Kodatef was made available for distribution on March 10, 2025, through a specialty pharmacy serving all 50 states
The Company is completing validation of two additional lots of Arakoda, to be released into the supply chain by early Q2 2025
We have another company for you to look at for tomorrows session.
This one just completed a reverse split like the two we looked at last week that took off.
Pull up SXTP.
60 Degrees Pharmaceuticals, a growth-oriented biotech company, specializes in the development and commercialization of new therapies used to treat and prevent serious infectious diseases.
Cutting-edge biological science and applied research form the foundation of their highly-focused, advanced clinical strategy.
In 2019, 60P’s malaria prevention product, ARAKODA® (tafenoquine), was made commercially available after receipt of U.S. regulatory approval in 2018.
60P is addressing the unmet medical need associated with infectious diseases through the development and commercialization of new small molecule therapeutics. By focusing on synthetic drugs (made by chemists in labs, excluding biologics) with good safety profiles based on prior clinical studies, 60P believes it has a cost- effective path to new indications that capitalizes on existing research to reduce costs and risk. 60P is expanding its commercialization efforts related to ARAKODA (tafenoquine), an antimalarial indicated for prophylaxis of malaria in patients 18 years and older and approved by the FDA in 2018. In Q2 2023, sales of ARAKODA increased by 150% relative to the same period in 2022, at an accelerating growth rate.
60P is implementing clinical research programs to evaluate the utility of the ARAKODA regimen of tafenoquine for non-malaria disease indications, with an upcoming planned Phase 2a study of tafenoquine in hospitalized babesiosis patients, with the goal of requesting a pre-IND meeting with FDA before the end of 2023. According to Company estimates, 47,000 cases of babesiosis (infections caused by red blood cell parasites similar to malaria that are transmitted by deer tick bites) occur in the United States each year, and the incidence rate is increasing. Estimates are that 10% of Lyme disease patients are co-infected with babesiosis. 60P is also testing the viability of another product (Celgosivir) to determine whether to advance it into further clinical development and may seek to develop and license other molecules in the future.
60° PHARMACEUTICALS’ PIPELINE OF INFECTIOUS DISEASE MEDICINES & INDICATIONS60° Pharmaceuticals (60P)—a growth-oriented specialty pharmaceutical company—is putting cutting-edge biological science and applied research to use in furthering therapies for the prevention and treatment of infectious diseases. Currently 60P’s pipeline covers promising clinical development programs for COVID-19, babesiosis, dengue and other viral illnesses.
ARAKODA FULFILLING THE PROMISE OF ARAKODA By leveraging its successful completion of clinical development and FDA approval of ARAKODA® (tafenoquine) for malaria prevention and exclusive research and licensing agreements with the U. S. Army, and with promising new non-clinical and clinical data in hand, 60P is seeking to evaluate the utility of tafenoquine for additional indications.
COVID-19 THERAPEUTIC TREATMENT The ARAKODA regimen of tafenoquine has exhibited positive Phase II study data in patients with mild-moderate COVID-19 disease.* Trial data has been published in New Microbes and New Infections, a peer-reviewed, open-access journal.
The study evaluated the safety and efficacy of tafenoquine in patients with mild-moderate COVID-19 diseaseLarger studies are planned to evaluate tafenoquine efficacy in treating COVID-19TREATMENT OF BABESIOSIS Tafenoquine exhibits useful activity in animal models of babesiosis and according to case reports may have clinical utility in treatment of drug-resistant strains.*
In collaboration with leading U.S. institutions, 60P is planning a proof of concept clinical study to assess the utility of ARAKODA as a treatment for human babesiosis.TREATMENT & PREVENTION OF FUNGAL DISEASESIn vitro and in vivo studies demonstrate that tafenoquine is effective for treatment and prevention of fungi such as Pneumocystis and yeasts at concentrations/doses that are clinically relevant.1,2* Pneumocystis remains an important pathogen in organ transplant patients for whom the current standard of care is sub-optimal in some patient segments.3 Many infections caused by yeasts such as Candida auris are refractory to standard of care medications such as azoles, amphotericin B, and echinocandins.2
60P’S CELGOSIVIR60P is planning a clinical development campaign for the repositioning of celgosivir, a host-targeted glucosidase inhibitor that was developed separately by other sponsors for HIV and hepatitis C4, but never approved by regulators. Similar to other dengue antivirals, celgosivir has shown diminished activity in curing dengue infection in animal models when administered after animals become symptomatic. However, this issue was addressed by administering the same dose split into four doses per day rather than one or two doses per daty.5 Preliminary data suggest celgosivir may inhibit the replication of the virus that causes COVID-19 (SARS-CoV-2) in cell culture, the RSV virus in cell culture, and may protect the lungs from RSV infection in animals.*
FY 2024 net product revenues increased 140% to $607.6 thousand.
FY 2024 gross profit increased $443.8 thousand from ($221 thousand) to $222.8 thousand.
WASHINGTON, March 28, 2025 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, reported today their financial results for the 2024 fiscal year, ended December 31, 2024.
Financial Highlights for the Fiscal Year Ended December 31, 2024:
Net product revenues increased 140% from $253.6 thousand for fiscal year 2023 to $607.6 thousand for fiscal year 2024; the Company credits growth from domestic commercial sales of ARAKODA®.
The Company achieved a gross profit of approximately $222.8 thousand in fiscal year 2024, compared to an approximate gross loss of $221 thousand in fiscal year 2023. Increased sales volume allowed the Company to overcome fixed cost of goods expense associated with the Drug Supply Chain Security Act that previously led to a gross loss.
Operating expenses were approximately $10.0 million in fiscal year 2024, compared with approximately $4.9 million in fiscal year 2023. The increase in operating expenses was primarily due to a non-recurring non-cash Research and Development charge of $2.63 million, non-recurring non-cash delivery of research materials ($0.6 million) and Research and Development costs associated with the Company’s babesiosis clinical trial program ($1.36 million).
Net loss attributable to common shareholders in calendar year 2024 was approximately $8.43 million, or $18.55 per share, compared with a net loss of approximately $3.925 million, or $59.18 per share in fiscal year 2023, representing a $4.505 million decline. This decline in profitability is mostly attributed to an increase in non-recurring non-cash Research and Development expenses of $3.23 million.
Recent Business Highlights
Due to a recent surge in demand for Arakoda® in the U.S. market, the Company submitted a regulatory discretion request to FDA in December 2024 to allow importation of Kodatef® (Australian-branded equivalent of Arakoda) to ensure continuous U.S. commercial supply. This was granted in February 2025, and Kodatef was made available for distribution on March 10, 2025, through a specialty pharmacy serving all 50 states.
The Company is completing validation of two additional lots of Arakoda, to be released into the supply chain by early Q2 2025.
Preparations for the Company’s commercial pilot are complete. Outreach to physicians commenced on March 17, 2025.
The Company commenced a randomized evaluation of tafenoquine versus placebo in hospitalized patients with babesiosis in 2024, randomizing N=6 of the minimum 24 patients required to trigger an interim endpoint (all completed the study). The Company recently increased its recruitment capacity for this study by establishing an additional clinical site at Brigham and Women’s Hospital. Interim analysis is expected in Q1 2026.
We initiated an open label evaluation of Arakoda in immunosuppressed patients who have a diagnosis of relapsing/persistent babesiosis. The first patient was enrolled during Q1, 2025. Up to 15 patients in total will be enrolled.
The epidemiological study sponsored by the Company, and conducted by North Carolina State University, is complete. The study evaluated the incidence of babesiosis by PCR and DNA sequencing in patients with persistent fatigue and neurological problems. Results of the study will be submitted to a peer-reviewed journal.
The total prevalence of post-infectious syndromes (severe chronic fatigue, chronic fatigue syndrome, encephalomyelitis, long COVID, and post-treatment Lyme disease syndrome), and the potential contribution of Babesia infection to that burden of disease, is not known. The Company is conducting additional market research to determine the size of these market segments in the U.S., with a view to defining an upper limit on the potential prevalence of chronic babesiosis.
The Company has secured IRB (ethics) approval for an open label evaluation of Arakoda in patients with severe fatigue and a presumptive diagnosis of babesiosis. The Company is now establishing the feasibility and cost of conducting such a study.
Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®
February 11, 2025 at 12:59 PM EST
WASHINGTON, Feb. 11, 2025 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), pharmaceutical company today announced that the United States Food and Drug Administration (FDA) does not object to the Company’s plan to import KODATEF® (tafenoquine) from Australia as a one-time, preemptive measure against any near-term disruption in the U.S. supply of ARAKODA® (tafenoquine).
ARAKODA is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years and older in the United States (U.S.) It is sold under the brand name KODATEF in Australia, where it is indicated for the prevention of malaria in adults 18 years of age and above. The two products are identical in their dosing regimens, mechanisms of action, safety and efficacy profiles, and other clinical features. KODATEF is not approved for use in the U.S.
Demand for ARAKODA has been steadily growing in recent months as awareness and use of the product has expanded across the U.S. The Company is taking the proactive step of importing KODATEF as a demonstration of its long-standing commitment to ensuring that tafenoquine for malaria prophylaxis remains readily available to healthcare providers at all times.
The Company plans to import a five-month supply of KODATEF while increasing manufacturing output of ARAKODA over the long-term.
A notice about this information is expected to be posted by FDA on its website.
About ARAKODA® (tafenoquine) Tafenoquine was discovered by Walter Reed Army Institute of Research. Tafenoquine was approved for malaria prophylaxis in 2018 in the United States as ARAKODA® and in Australia as KODATEF®. Both were commercially launched in 2019 and are currently distributed through pharmaceutical wholesaler networks in each respective country. They are available at retail pharmacies as a prescription-only malaria prevention drug. According to the Centers for Disease Control and Prevention, the long terminal half-life of tafenoquine, which is approximately 16 days, offers the advantage of less frequent dosing for the prophylaxis of malaria. ARAKODA® is not suitable for everyone, and patients and prescribers should review the Important Safety Information below. Individuals at risk of contracting malaria are prescribed ARAKODA® 2 x 100 mg tablets once per day for three days (the loading phase) prior to travel to an area of the world where malaria is endemic, 2 x 100 mg tablets weekly for up to six months during travel, then 2 x 100 mg in the week following travel.
60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis
Investigational Review Board (IRB) approval has been granted for the open-label study to evaluate tafenoquine for treatment of patients with a presumptive diagnosis of chronic babesiosis in outpatient settings.
Enrollment expected to commence Q3 2025.
WASHINGTON, Jan. 28, 2025 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today the approval of an Investigational Review Board (IRB) sanctioned Phase II clinical study.
The study (NCT06656351) will evaluate the efficacy and safety of the ARAKODA® regimen (tafenoquine) over 90 days for treating patients with a presumptive diagnosis of chronic babesiosis. Participants will have experienced significant functional impairment for at least six months. Patient enrollment is expected to begin in Q3 2025.
“As babesiosis continues to emerge in new regions of the U.S., the need to address its impact safely and effectively is also growing,” said 60 Degrees Pharmaceuticals, Inc. Chief Executive Officer, Geoff Dow, PhD. “The chronic phase of babesiosis particularly may prove to be one of the most important areas of study due to the estimated large size of the patient population, the severity and duration of symptoms, and the absence of any approved treatment option available today.”
The Company estimates the total cumulative addressable market through the end of U.S. patent protection in December 2035 for ARAKODA (tafenoquine) for babesiosis exceeds 400,000 patients.
About Babesiosis Babesiosis is a tick-borne illness caused by Babesia parasites that develop and multiply in red blood cells. Its symptoms include fevers, chills, sweats, and fatigue, and in severe cases, can be life-threatening threatening in elderly and immunosuppressed patients. Incidence of the disease is rapidly rising, particularly in the Northeast. Transmitted through the bite of the black-legged (deer) tick, the vector that spreads Lyme disease, babesiosis is an orphan disease. Babesia infection may persist for at least a year; fatigue is usually the symptom of infection that takes longest to resolve and may be debilitating over the long term in some patients.
Geoffrey Dow is the CEO, President, and a Director of 60 Degrees Pharmaceuticals, Inc. (60P). He has over 20 years of experience in product development for tropical diseases and a strong publication and patent history. He has 13 years of leadership and advisory experience in the antimalarial drug development program at the Walter Reed Army Institute of Research and the U.S. Army Medical Materiel Development Activity. Dr. Dow co-founded 60P in 2010 and has been instrumental in various projects including securing FDA-regulatory approval for tafenoquine (Arakoda) for malaria prophylaxis, managing post-marketing regulatory commitments, and ensuring the company adheres to GMP, quality, and pharmacovigilance requirements. He has also published several important safety reviews, clinical trials, and non-clinical studies. Dr. Dow’s ultimate goal is to develop and secure regulatory approval and commercial success of products for new indications in infectious disease. He holds a B.Sc. (Hons) in Veterinary and Biomedical Science from Murdoch University, Perth, Western Australia (1994), a Ph.D. in Veterinary and Biomedical Science from Murdoch University (2000), and an MBA from the University of Maryland at College Park (2012).
Bryan Smith
Chief Medical Officer
Bryan Smith is the Chief Medical Officer of 60 Degrees Pharmaceuticals, Inc. (60P). He is a medical doctor with expertise in clinical pharmacology, pharmacovigilance, regulatory strategy development, and translational medicine. He has over 30 years of experience in governmental research and leadership and is a retired military colonel. He joined the company in 2016 and works with the senior management team to establish all functional areas, including compliance with laws and regulations and overseeing research and development projects. Dr. Smith is also a Senior Medical Director, Clinical and Regulatory Affairs at Fast-Track Drugs & Biologics, LLC since 2019, where he is responsible for developing clinical development plans, managing clinical and regulatory projects, and designing and writing clinical trial protocols. He has also served as the Chief Medical Officer and member of Amivas LLC, where he established all functional areas required to secure FDA approvals. Additionally, from 2016 to 2019, he was the Principal Medical Consultant at Clinical Network Services, Inc. where he provided medical, clinical pharmacology, regulatory, and translational medicine review, oversight and consultation as requested for over 25 unique clients in a range of activities and tasks for devices, small molecules, and large molecules in a range of therapeutic areas. He holds a Bachelor of Science in General Science, with highest honors, from Oregon State University and a Doctor of Medicine from Uniformed Services University of the Health Sciences.
Tyrone Miller
Treasurer
Tyrone Miller is the Treasurer of 60 Degrees Pharmaceuticals, Inc. (60P). He joined the company in 2014 and has held various roles including Chief Financial Officer. He has experience raising over $6 million in external financing and established a multinational financial reporting system. He provides strategic advice in areas of financing and business planning to the company. He is also the founder and Principal of Tax & Accounting Practice at Miller Tax & Advisory since 2011, where he advises business owners on accounting, financial, and tax matters and has designed accounting systems for private businesses. Prior to that, he was a Senior Accountant at Sachs Figurelli, LLC from 2002 to 2011 where he prepared and processed corporate and individual tax returns, consulted on accounting processes for various businesses, and managed staff in preparation and processing of payroll and personal property returns. He is a Certified Public Accountant and received a Bachelor’s of Business Administration with a concentration in International Business from Emory University in 1996.
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SIX THOUSAND USD BY SHORE THING MEDIA LLC FOR A ONE DAY SXTP AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
There was blood in the water last week and more of the same is expected Monday as of right now anyway.
With that being said, we found a detour last week. Our profile from wed ran over 20% while Thursdays profile was on the verge of going parabolic after opening at 4.89 and hitting 7.95 later on in the session. That one got halted twice for tripping the circuit breaker and making huge moves to the upside.
Moving on we have a new profile with a TINY float that have probably never heard of before.
Pull up NTRP right away.
Take a look at the chart on this one! Since December this one has exploded and established itself a new trading range.
NTRP has the potential to break out as evidenced by the chart above. Right now is a goo time to research this one.
NextTrip (NASDAQ: NTRP) is a technology-driven platform that revolutionizes the way travelers book vacations and consume travel media. Leveraging advanced travel technology, a state-of-the-art booking engine, and AI-assisted travel planning, NextTrip integrates innovative digital solutions with personalized travel services. The platform is designed for individual and group travelers seeking vacations to popular destinations in Mexico, the Caribbean, and around the world. Keywords such as ‘travel technology’, ‘AI-assisted planning’, and ‘digital booking engine’ highlight its commitment to using technology as a catalyst for transformation in the travel sector.
NextTrip operates across two primary segments:
Travel Booking Services: This division, known as NextTrip Leisure, provides end-to-end travel booking solutions. It combines a robust booking engine with a personalized concierge team to assist travelers in arranging vacations. The solution is enhanced by features that facilitate group travel and cater to diverse customer needs.
Travel Media Solutions: The company’s media arm, featuring the Travel Magazine platform and Compass.tv travel discovery channel, serves as an interactive social media venue. Here, viewers can explore travel destinations, discover content curated by industry influencers, and share ‘bucket list’ experiences. This media integration is strategically designed to convert engaging content directly into commerce opportunities.
Business Model
At the heart of NextTrip’s operations is its innovative use of digital technologies. The company utilizes AI-assisted travel planning tools to provide tailored travel recommendations and integrate real-time data into its booking process. Its proprietary booking engine is designed not only to handle traditional reservations but also to incorporate product expansions such as white-label offerings and embeddable booking widgets for third-party partners. This creates diversified revenue channels, spanning direct bookings, advertising, and licensing of technology.
NextTrip positions itself at the intersection of travel technology and digital media, uniquely combining a booking engine with immersive travel content. Unlike traditional travel agencies that focus exclusively on reservations, NextTrip’s dual approach of media content and booking solutions fosters engagement and builds brand loyalty among consumers. Its strategic partnerships with renowned digital media specialists and influencers further enhance its market credibility and competitive positioning. By integrating content-to-commerce funnels, the company capitalizes on rising consumer trends in digital content consumption and targeted advertising, setting it apart in the travel technology space.
The company offers:
Personalized Travel Experiences: Through AI-assisted planning and a comprehensive concierge service, travelers receive customized vacation recommendation and support throughout their journey.
Integrated Media and Commerce: With platforms such as Travel Magazine and Compass.tv, NextTrip transforms engaging travel content into direct booking opportunities, creating a seamless transition from inspiration to action.
Diverse Revenue Streams: Its business model includes direct consumer bookings, advertising on travel content platforms, and technology licensing, ensuring a broad base of revenue sources.
NextTrip Closes on 49% Stake in Five Star Alliance
Secures Option to Acquire Full Ownership
SANTA FE, NM / ACCESS Newswire / February 11, 2025 / NextTrip, Inc. (NASDAQ:NTRP) (“NextTrip” or the “Company”), a leading travel technology company, today announced it has closed its previously announced acquisition of a 49% stake in Five Star Alliance, a premier luxury travel agency. As part of the transaction, NextTrip has secured an option to acquire full ownership of Five Star on or before April 7, 2025, subject to certain conditions.
The acquisition was funded through a combination of cash on hand and NextTrip shares, with terms based on the November 2024 Letter of Intent (LOI). The acquisition is expected to be accretive to earnings, leveraging shared technology, supplier relationships, and customer networks to drive growth.
Founded in 2004, Five Star Alliance specializes in five-star hotels and resorts worldwide, offering a curated selection of over 5,000 luxury properties. With a 4.9-star Trustpilot rating, the company is known for its exclusive rates and personalized service.
A Shared Vision for Luxury Travel
“We are excited to join forces with NextTrip to deliver a seamless luxury travel experience,” said John P. McMahon, CEO and significant owner of Five Star Alliance. “Unlike traditional online travel agencies, we prioritize the traveler, offering the best rates, exclusive perks, and premium service. Partnering with NextTrip allows us to scale while maintaining our commitment to exceptional customer experiences.”
As a part of the initial transaction, Mr. McMahon has joined the NextTrip management team.
For details, please refer to NextTrip’s Current Reports on Form 8-K filed with the SEC relating to this transaction.
About Five Star Alliance
Five Star Alliance has been a leader in luxury travel by offering the most comprehensive, hand-picked collection of five-star luxury hotels and resorts worldwide since 2005. Backed by an award-winning staff to guide and assist guests throughout their entire journey, Five Star Alliance provides a full range of travel products including airfare, transportation, luxury river and ocean cruises, group and meeting services, concierge services, and more. Five Star boasts an industry-leading customer satisfaction rating of 4.9 stars on Trustpilot. For more information visit www.fivestaralliance.com.
NextTrip Reports Strong Growth in Group Bookings Following Five Star Alliance Collaboration
NextTrip has Secured 300 Traveler Bookings, Totaling 1,480 Room Nights, Expected to Generate Several Hundred Thousand Dollars in Revenue Upon Travel
SANTA FE, NM / ACCESS Newswire / April 1, 2025 / NextTrip, Inc. (NASDAQ:NTRP) (“NextTrip,” “we,” “our,” or the “Company”), a leading travel technology company dedicated to transforming how travelers plan, book, and experience trips, today announced significant progress in Group Booking activity and lead conversions following its recent collaboration with Five Star Alliance. NextTrip announced the launch of its Group Booking Platform last summer, designed to modernize and streamline a traditionally manual and cumbersome process, bringing efficiency and ease to travelers and group organizers alike.
In February of this year, NextTrip acquired a 49% stake in Five Star Alliance, a premier online luxury travel agency founded in 2004 and renowned for its curated collection of five-star hotels and resorts worldwide. While Five Star Alliance historically received frequent group booking inquiries, its primary focus remained on luxury travel and high-end hotel reservations.
Following the acquisition and subsequent business collaboration, these group inquiries are now seamlessly integrated into NextTrip’s ecosystem, allowing for optimized handling and higher conversion rates. Leveraging NextTrip Group’s proprietary technology, strong hotel partnerships, and exceptional customer service, the company has achieved an impressive 75% conversion rate on Five Star Alliance group inquiries.
In recent weeks alone, NextTrip has successfully secured bookings for 300 travelers for a total of 1,480 room nights booked, which will generate several hundred thousand dollars in revenue for NextTrip at time of travel. The company attributes this success to its innovative technology and user-friendly booking process, which streamlines group travel logistics while maintaining competitive rate negotiation and personalized customer service. With this scalable model, management believes that NextTrip is well positioned for continued growth in the group travel market.
NextTrip’s cutting-edge platform allows individual travelers within a group to book their own travel at their convenience while still remaining part of the collective reservation. This customizable technology also streamlines corporate and incentive groups, reducing the administrative burden on group leaders. They are now able to remove themselves from having to coordinate and collect flight details, travel dates, and room preferences. The guests are also able to add pre-and-post nights to their reservation, activities, insurance, and more. To enhance accessibility, the Group Booking Platform can be integrated into various digital touchpoints, including email invitations, event landing pages, and conference websites, ensuring seamless engagement and streamlined travel management. The feedback received on customer service, booking experience, and curated deliverables has been highly favorable.
As NextTrip continues to expand its Group Booking capabilities, the Company remains committed to leveraging technology to enhance the travel experience for groups of all sizes. For more information, visit NextTrip.com/groups.
NextTrip Strengthens Financial Position with the Conversion of $2.6 Million in Short-Term Debt to Restricted Equity Before its Fiscal Year-End
Provides for a Stronger Balance Sheet and Greater Financial Flexibility to Focus on Scaling Innovative Travel Solutions
SANTA FE, NM / ACCESS Newswire / February 28, 2025 / NextTrip, Inc. (NASDAQ:NTRP) (“NextTrip,” “we,” “our,” or the “Company”), a leading travel technology company, announced today the conversion of $2.6 million in short-term debt, including $1.5 million previously advanced by the Company’s Chairman and CEO. These loans were converted into restricted equity ahead of completion of the Company’s fiscal year-ended February 28, 2025. Additionally, certain other creditors agreed to convert their $1.1 million of debt into restricted equity. This is in addition to the $1.75 million in short-term promissory notes previously converted to restricted equity on December 31, 2024.
These strategic moves eliminate most of the debt from NextTrip’s balance sheet, replacing cash repayment obligations, including for accrued principal and interest, with the issuance of restricted shares of the Company’s stock. This significantly enhances the Company’s balance sheet and frees up capital to drive key initiatives. The Company believes this underscores strong insider confidence in NextTrip’s long-term growth trajectory while enhancing financial flexibility as it enters fiscal year 2026.
“The conversion of these substantial loans reflects our unwavering support and commitment to NextTrip’s future,” said William Kerby, NextTrip CEO. “With a stronger balance sheet and greater financial flexibility, we are better positioned to manage our obligations effectively and focus on scaling our innovative travel solutions.”
NEWS
NextTrip Holdings and Intimate Hotels of Barbados Forge Strategic Partnership to Enhance Caribbean Travel Experience
4/3/25 9:01
NextTrip Reports Strong Growth in Group Bookings Following Five Star Alliance Collaboration
4/1/25 9:01
NextTrip Launches New Innovative Online Cruise Booking Platform NextTrip Cruise
3/27/25 9:01
NextTrip Strengthens Financial Position with the Conversion of $2.6 Million in Short-Term Debt to Restricted Equity Before its Fiscal Year-End
2/28/25 9:01
NextTrip and Blue Fysh Announce Strategic Partnership and Share Exchange Agreement to Drive Mutual Growth
2/27/25 9:01
NextTrip Appoints John McMahon as Chief Operating Officer – Travel, Expands into Cruise Industry with Five Star Alliance
2/25/25 9:01
NextTrip Announces Launch of Compass.TV Apple iOS and Google Android Apps
2/13/25 9:01
NextTrip Closes on 49% Stake in Five Star Alliance
2/11/25 8:50
NextTrip Invests in Luxury Travel Brand Five Star Alliance to secure 49% Stake with an Option to Purchase a Controlling Interest
2/6/25 16:30
NextTrip Launches Advertising on Compass.tv in Collaboration with Leap Media Group
12/3/24 9:01
MANAGEMENT
Bill Kerby
Founder & CEO
Bill Kerby brings more than two decades of experience in the travel and media industries, and approximately a decade of experience in the financial industry. He has extensive experience bringing companies into public markets in both the TSX and Nasdaq, serving as CEO for various travel and media companies including Maupintour, Extraordinary Vacations, Travelbyus and Leisure Canada.
Frank Orzechowski
Chief Financial Officer & Corporate Secretary
Frank Orzechowski serves as Chief Financial Officer, bringing significant experience leading financial operations across the public and private sectors. He previously served as the Chief Financial Officer of Storm Harbour Partners LP, an independent global markets and financial advisory firm. Prior to that, he held a variety of senior executive positions, primarily in the financial services industry. He began his career at Coopers & Lybrand, and is a Certified Public Accountant.
John McMahon
Chief Operating Officer – Travel Division
John brings a proven track record in the leisure, travel, and tourism industry, McMahon brings extensive expertise in management, marketing strategy, digital marketing, online distribution, social media, and business development. His deep industry relationships, spanning from C-level executives to on-the-ground professionals.
Loic Argelies
Chief Product Officer
Loic brings over 20 years of management and technical expertise in media, streaming, and gaming products. Previously, he served as Chief Product Officer and Co-Founder of Promethean TV, as well as Vice President of Products and Partnerships at AZUBU, an eSports and streaming company. Earlier in his career, Loic held key roles at Electronic Arts, including Senior Engineer, Technical Director, and EA Sports Producer.
Amy Proost
Chief Sales & Ops. Officer
Amy Proost is a seasoned travel executive with more than 25 years of experience across the OTA and wholesale space. Amy brings strong operational knowledge, deep industry relationships and a relationship-focused approach to growing the business.
Richard Marshall
Director of Corporate Development
Richard Marshall has 30 years of senior executive experience generating growth and developing relationships for global corporations. Previously, he was Director of Corporate Development at Monaker Group & NextPlay. He was also VP of IR and VP corporate development at NYSE-traded natural resources company, securing $600 million in financings during his 18-year tenure. Part of company’s team that won WorldBank ICSID $1.4 Billion Award.
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF THREE THOUSAND FIVE HUNDRED USD BY GREEN MONSTER CAPITAL INC FOR A ONE DAY NTRP AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
Today’s profile did not disappoint and closed up 20% after made another run at the high of the day and smashed it around 3:30. During the session it dipped as low as 3.01 before rocketing all the way to 3.72. Keep in mind that this one just did a reverse split as we move onto the next one.
We have another profile back on deck for tomorrow’s session.
This one just executed a 10 for 1 reverse split on Monday, drastically reducing the outstanding on this one.
We want you to pull up VMAR immediately.
If you like volatility then you will certainly like VMAR. If you look at the chart you will see that this one has had some wild swings over the past year, most coinciding with substantial news announcements. After the recent reverse it only makes sense that VMAR would have less resistance in the way as of right now.
This may be why it EXPLODED all the way to 9.53 this morning on massive interest. VMAR has backed off of those highs substantially but we know that this one can move and shake but it is all about timing and research. You are going to want to research this one thoroughly and keep it on your screen.
‘Vision Marine Technologies, Inc., (NASDAQ: VMAR) strives to change and be a contributing factor in fighting the problem of waterway pollution by disrupting the boating industry with electric power, contributing to zero pollution, zero emission, wave less water, and a noiseless environment.
The Company’s flagship outboard powertrain is the first fully electric outboard motor that combines an advanced battery pack, inverter, and high efficiency motor.
They continue to design, innovate, manufacture, and sell handcrafted, high performance, environmentally friendly, electric recreational powerboats to recreational customers. The design and technology applied to their boats results in far greater and enhanced performance, higher speeds and longer range. Simply stated, VMAR is responsible for providing a smoother ride than a traditional ICE motorboat.
Electric motors are often considered superior to internal combustion engines (ICE) for several reasons. They are more energy-efficient, converting a higher percentage of electrical energy into mechanical power with less waste in the form of heat. Electric motors also have fewer moving parts, which leads to reduced wear and tear, lower maintenance costs, and longer lifespans. Furthermore, electric motors can provide instant torque, delivering smoother and more responsive performance, especially in applications like electric vehicles. From an environmental perspective, electric motors are more sustainable, as they can be powered by renewable energy sources, reducing dependence on fossil fuels and lowering overall carbon emissions.
Vision Marine Technologies Achieves European CE Certification for E-Motion(TM) Equipped Electric Boat
MONTRÉAL, QC / ACCESS Newswire / January 31, 2025 / Vision Marine Technologies Inc. (the “Company”, “Vision Marine”, “we”, “us”, “our”) (Nasdaq:VMAR), a leading innovator in electric marine propulsion, proudly announces that one of our boats integrated with our groundbreaking E-Motion™ 180E Electric Marine HV Powertrain has successfully received “CE” certification or European conformity. This milestone marks Vision Marine’sstrategic push toward greater penetration in the European market with its electric marine powertrain products, showcasing its product’s readiness to meet the European Economic Area’s demand for sustainable and high-performance boating solutions.
Our “CE” certification is a pivotal step in Vision Marine’s European strategy. After numerous successful integrations of the E-Motion™ 180E system into boats produced by European manufacturers, obtaining “CE” certification on this first boat was the logical progression to obtain compliance with the region’s rigorous standards.
The European marine industry appears to be at the forefront of electric propulsion adoption, driven by a strong emphasis on sustainability and regulatory support. Market research projects the global electric boats market to expand from USD $3.3 billion in 2023 to USD $7.7 billion by 2030, at a Compound Annual Growth Rate (CAGR) of 13.0% (MarketsandMarkets). Europe’s own market, valued at USD 2,090.69 million in 2022, is forecasted to grow to USD $4,404.83 million by 2028 at a CAGR of 13.2% (Business Market Insights). We believe Vision Marine’s ability to align with this market shift may position its cutting-edge E-Motion™ system as a key enabler for manufacturers striving to meet these evolving demands.
This certification milestone highlights the importance of the European market for Vision Marine Technologies, where we believe the rapid adoption of electric propulsion underscores the growing potential for advanced solutions. Achieving CE certification eliminates a significant barrier for manufacturers, signaling Vision Marine’s readiness to provide innovative and what we believe to be reliable electric systems tailored to European standards. By aligning its engineering excellence with the region’s evolving needs, we believe Vision Marine is well-positioned to support manufacturers in delivering next-generation marine products and capturing opportunities in the expanding global electric boating market. Moreover, this milestone further exemplifies Vision Marine’s commitment to position itself in order to drive sustainable innovation and foster long-term growth within the European market with our electric propulsion solutions.We believe this achievement validates our E-Motion™ 180E Electric Marine HV Powertrain system’s performance, reliability, and compatibility, and is likely to encourage manufacturers to adopt Vision Marine’s cutting-edge electric propulsion solutions as part of their product lines.
“Achieving CE certification is an important milestone for Vision Marine as we continue our expansion into the European market,” noted Alexandre Mongeon, CEO of Vision Marine. “This accomplishment underscores our commitment to providing world-class electric powertrain systems that meet the highest standards of safety and performance. While we advance in Europe, we remain steadfast in pushing the boundaries of electric marine innovation in the American market.”
Vision Marine Technologies Innovates HV Marine Battery Packs in Collaboration With Calip Group
MONTREAL, QC / ACCESSWIRE / January 9, 2025 / Vision Marine Technologies Inc.(the “Company”, “Vision Marine”, “we”, “us”, “our”) (Nasdaq:VMAR), a leading innovator in electric marine propulsion, announces the establishment of a production line for custom cooling plates in partnership with Calip Group, a leader in high-tech welding processes. Under this collaboration, Calip Group will supply components that enhance the thermal management of Vision Marine’s high-voltage (HV) marine battery packs. These custom cooling plates are specifically tailored to meet the stringent demands of marine applications, with production slated to begin in 2025.
Marine battery packs operate in environments that demand sustained, high-power delivery over extended periods. In contrast, most high-voltage batteries are designed to provide only brief bursts of peak power and minimal continuous output. Marine applications, however, require continuous operation at elevated power levels, resulting in significant thermal stresses that can degrade battery cells and shorten their lifespan.
To address these challenges, Vision Marine has developed specialized cooling plates adapted to the unique thermal requirements of marine battery packs. By improving heat dissipation and stabilizing cell temperatures, these advanced cooling plates help maintain consistent performance, enhance reliability, and extend the operational life of the cells – even under the most rigorous marine conditions.
“Overheating in a high-voltage battery designed for marine applications is a real challenge,” said Xavier Montagne, Technical Director of Vision Marine. “We decided to design our own specialized cooling plate to enhance pack stability and, of course, increase thermal efficiency.”Calip Group contributed its technical expertise through its FSW (Friction Stir Welding) welding process, enabling the precise manufacture of fully sealed cooling plates.
“We adapted our industrial tooling to meet the exact constraints of the battery and its specific assembly process,” said Thierry Giorgalla, General Director of Calip Group. “We’ve invested heavily in fine-tuning our FSW welding method to ensure a fully sealed cooling plate within tight tolerances. Calip is among the European leaders at mastering this high-tech process.”
Vision Marine’s E-Motion™ Powerpacks remain at the forefront of high-voltage marine battery technology. Among the first battery packs specifically designed for electric marine propulsion, they feature IP67-rated stainless-steel construction for superior durability, advanced thermal management systems, and modular configurations that seamlessly integrate into boats ranging from 18 to 34 feet. Vision Marine’s meticulous engineering has ensured that the E-Motion Powerpacks operate with unparalleled safety and reliability, with no recorded instances of thermal runaway to date. This impeccable track record, paired with new custom cooling plates developed alongside Calip Group, underscores Vision Marine’s commitment to proactive innovation and safety. Combined with full ownership of the tooling and strong production partnerships, the company is poised to scale manufacturing efficiently and reliably, meeting the rising market demand with confidence.
This development underscores Vision Marines’ commitment to delivering advanced, reliable, and practical solutions that foster the adoption of sustainable marine propulsion systems. This production agreement with Calip Group is yet another step toward meeting growing market demand for high-performance electric boating technologies.
About Calip Group: Calip Group is a leading alliance of two precision mechanics specialists, Calip Normandie and MGF Grimaldi. Founded in 2014, the group meets the stringent requirements of major industrial sectors, including aerospace, automotive, defense, medical, and robotics. With a workforce of 400 skilled employees and the production strength of five facilities across France and Romania, Calip Group delivers innovative, high-precision manufacturing solutions. In 2024, the group expanded its capabilities with the acquisition of SPEMA, a company specializing in high-precision mechanics. By integrating lean management practices, innovative processes, and a streamlined supply chain for surface treatments and painting, Calip Group has evolved from a machining subcontractor into a full-scale serial producer of complex components.
Vision Marine Expands Partnership With Aileron Residences to Launch Electric Boat Rentals and Retail Hub in South Florida
This partnership provides Vision Marine with essential dock space and storage, allowing for a phased rollout of rental operations with on-site Company presence. Additionally, Vision Marine intends to open its new point of sale (“POS”) location to strengthen its foothold in the Florida market by providing early exposure to its products and services, which is expected to solidify its long-term growth strategy.”This partnership marks a significant step in integrating electric boating into luxury real estate” said Maxime Poudrier, Head of Growth & Strategic Partnerships at Vision Marine Technologies. “Aileron Residences expects to set a new standard by offering not only seamless access to our electric boat club but also a platform for introducing cutting-edge 180E E-Motion electric boats. This location will serve as a launchpad for innovative electric boating solutions, redefining the marine experience with minimal environmental impact.”
“As a waterfront community, we wanted to go beyond just offering scenic views and create an immersive experience,” said David Lynd, President and CEO of LYND. “Partnering with Vision Marine allows us to deliver a truly unique, high-end amenity that will align with the future of luxury real estate. Our eventual residents will have instant, effortless access to a fleet of state-of-the-art electric boats, eliminating the complexities of ownership while enhancing their connection to the water.”
With this partnership, Vision Marine Electric Boat Rental intends to roll out operations in phases at Aileron Residences, offering rental services while preparing for the full integration of its electric boating solutions into the community. This plan underscores Vision Marine’s strategic vision within the development, that may enable Aileron to become a key destination for sustainable marine recreation.
Furthermore, Vision Marine’s eventually expanded presence at Aileron Residences is expected to include the a key retail hub for electric marine technology, enabling both eventual residents and visitors to purchase cutting-edge electric boating solutions directly on-site. We believe South Florida is recognized as one of the most vibrant boating hubs in the world and will provide an ideal setting for Vision Marine’s continued expansion in the luxury waterfront sector.
Seamless Boating for Aileron Eventual ResidentsAileron Residences plans to enhance its future community by integrating Vision Marine’s electric boating solutions and offering flexible membership options for eventual residents. Standard membership is expected to provide on-demand reservations, while optional Prime Membership is expected to offer priority booking, early access to the latest electric boats, and invitations to exclusive waterfront events.
Additionally, Vision Marine Electric Boat Rental is expected to offer hourly rental options, so that both eventual residents and guests, including first-time users, can enjoy the benefits of electric boating with ease and without long-term commitments.
Having facilitated over 60,000 electric boat rentals across various locations, Vision Marine Electric Boat Rental continues to enhance the recreational boating landscape by combining industry-leading technology with user-friendly access.
As South Florida appears to solidify its status as a global luxury destination, Vision Marine’s eventual presence at Aileron Residences is expected to reinforce its position as a pioneering force in the next generation of marine mobility.
Vision Marine Technologies Files Patent Application for Proprietary Battery Encryption System
Safeguarding Advanced Powertrain Technology and Boaters’ Data from Third-Party Substitution
MONTREAL, QC / ACCESSWIRE / January 14, 2025 / Vision Marine Technologies Inc.(the “Company,” “Vision Marine,” “we,” “us,” “our”) (Nasdaq:VMAR) is pleased to announce the filing of its latest patent application with the United States Patent and Trademark Office for a groundbreaking Battery Authentication Encryption Technology. This system is designed to securely integrate proprietary components within the E-Motion™ Electric Powertrain, prevent third-party substitution, and gather valuable boaters’ data, reinforcing the strategic value of Vision Marine’s advanced technology.
“The importance of system security cannot be overstated as we transition into a digital marine era,” said Xavier Montagne, Chief Technology Officer at Vision Marine. “This patent application is the result of several years of research and development to make high-voltage systems compatible with the nautical field. Our unique skills in electronics and embedded software and our long experience in electric propulsion have made it happen.”
The technology employs a sophisticated Battery Management Controller (BMC) to authenticate components within the powertrain. This helps ensure that only Vision Marine’s proprietary components function in harmony with the system, eliminating risks associated with third-party substitutions that could compromise performance or safety. Beyond enhancing the system’s security, this innovation enables the collection and analysis of boaters’ data, a critical component in driving superior system performance and customer satisfaction.
“Our investment in developing a robust data-driven system is now yielding significant benefits,” said Alexandre Mongeon, CEO of Vision Marine Technologies. “By empowering Xavier Montagne and his team to focus on building this cutting-edge technology, we’ve created a platform that enhances system functionality while providing valuable insights through data analysis. This approach not only improves our products and services but also highlights the scalability and long-term value of our business for investors.”
The data gathered from Vision Marine’s proprietary system allows the Company to continually optimize product performance and deliver tailored solutions for boat Manufacturers and boaters. This data-rich foundation not only improves system reliability but also serves as a strategic asset that drives innovation, supports customer retention, and unlocks potential new revenue streams.
By preparing the technology behind this patent application, Vision Marine reaffirms its commitment to advancing electric propulsion technology while ensuring the integrity, exclusivity, and data-driven intelligence of its proprietary ecosystem.
__________
Vision Marine Technologies and Massimo Marine Announce Production Partnership for First Commercial Electric Pontoon Platform
MONTREAL, QC / ACCESSWIRE / December 1, 2024 / Vision Marine Technologies Inc. (the “Company”, “Vision Marine”, “we”, “us”, “our”) (Nasdaq:VMAR), a pioneer in electric marine propulsion, has entered into a milestone partnership with Massimo Marine, the marine division of Massimo Group (MAMO). This collaboration will produce a fully integrated 30-foot electric pontoon platform designed for commercial and recreational markets. As part of Vision Marine’s strategic shift to offer complete electric boats directly to consumers, this partnership represents a key step in rapidly delivering high-quality electric marine products to market.
Vision Marine and Armada Partner to Produce an Innovative Electric Pontoon for North America’s Regulated Lakes
MONTRÉAL, QUEBEC / ACCESSWIRE / December 8, 2024 / Vision Marine Technologies Inc. (the “Company,” “Vision Marine,” “we,” “us,” “our”) (Nasdaq:VMAR), a pioneer in electric marine propulsion, has announced a strategic partnership with Armada Pontoons, a renowned manufacturer of high-quality pontoon boats based in Quebec, Canada. This collaboration introduces a new electric pontoon boat designed to meet the growing demand for eco-friendly, regulation-compliant, and competitively priced boating solutions for North America’s vast network of lakes.
Many lakes across North America, particularly in states like Georgia, North Carolina, Ohio, and Pennsylvania, have implemented restrictions that allow only electric motors to protect ecosystems and reduce pollution. While comprehensive data on the total number of waterways with such regulations is unavailable, the scale of the opportunity is clear. With approximately 479,950 lakes and reservoirs in the contiguous United States and over 3 million lakes in Canada, pontoons-celebrated for their versatility and stability-remain one of the fastest-growing segments in the marine industry. This electric pontoon is uniquely positioned to address growing demand, offering families an eco-friendly and seamless on-water experience tailored for these regulated environments.
ePropulsion Teams Up with Vision Marine Technologies to Unveil and Propel the Phantom Plastic Boat
MONTREAL, QC / ACCESSWIRE / September 10, 2024 / Vision Marine Technologies, Inc. (NASDAQ:VMAR) (“Vision Marine” or the “Company”),a pioneer in electric marine propulsion, announces its strategic alliance with ePropulsion to empower the groundbreaking Phantom Boat, crafted from innovative plastic rotomolding technology. Following its debut at the Miami International Boat Show, the Phantom is set to showcase a customized electric ePropulsion system. In this partnership, the Phantom will be available through select ePropulsion dealers, both on request and by recommendation across its dealer network.
For over a decade, Vision Marine Electric Boats has relied on ePropulsion for its cutting-edge low-voltage boat propulsion solutions across its product line and to energize its rental boat fleet. This enduring collaboration underscores Vision Marine’s commitment to quality and the dependability of ePropulsion’s equipment, which has powered over 385,000 boaters in demanding rental environments worldwide.
Vision Marine Technologies Partners with JetRide to Leverage Growing Electric Boat Rental Market
MONTREAL, QC / ACCESSWIRE / June 20, 2024 / Vision Marine Technologies, Inc.(NASDAQ:VMAR) (“Vision Marine” or the “Company”),a pioneer in electric marine propulsion, is thrilled to announce its partnership with JetRide Holding, LLC, a Floridamembers-only boat club. This strategic alliance marks Vision Marine’s expansion in the burgeoning electric boat rental market, leveraging JetRide’s extensive network of over 17 boat club locations across Florida.
We believe the electric boat market is experiencing rapid growth, driven by increasing awareness and demand among both seasoned boaters and newcomers. Similar to the rise of electric cars, we believe that electric boats are becoming essential in the boating world, offering innovative solutions and unique experiences. Electric boating not only attracts existing boaters but also encourages non-boaters to explore and enjoy the pleasures of boating for the first time. Renters will have the opportunity to experience Vision Marine’s E-Motion™ Electric Powertrain firsthand, along with a variety of other electric products, all supported by years of expertise in electric boating.
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF EIGHT THOUSAND FIVE HUNDRED USD BY SHORE THING MEDIA LLC FOR A ONE DAY VMAR AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
HUBC has secured contracts from ING, Boeing & Visa to name a few – Fortune 500 companies, startups, and government agencies are signing up for HUBC’s state-of-the-art cybersecurity solutions
HUB Cyber Security Resolves $16.6 Million in Legacy Liabilities through Strategic Settlements with Oppenheimer & Co. and Dominion Capital; Secures $13.5 Million Financing on Favorable Terms
HUB Cyber Security Secures Six-Month Extension on $11M Notes, and Strengthens Shareholder Equity
HUBCdv operates in over 30 countries and provides innovative cybersecurity computing appliances as well as a wide range of cybersecurity professional services worldwide.
HUB is acquiring BlackSwan Technologies, a leader in AI-driven secured data fabric solutions. This acquisition makes us a dominant force in data protection & compliance, powered by $50M of innovation. #CyberSecurity#DataFabrichttps://t.co/z8VKYsNXV9
We have a past winner back on our radar for Wednesdays session. One of the times we looked at this one in the past it just about doubled in 3 sessions.
Since the last time we looked at HUBC they have had some major news.
Most importantly they just had a 1-for-10 reverse share split take place last Friday.
This is a great time to research this one because they just drastically reduced the float on HUBC with this move.
We just saw it explode today all the way back up to 3.32.
We are going to want to keep a close eye on this one when the bell rings.
HUB Announces Reverse Share Split
TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) — Hub Cyber Security Ltd.(Nasdaq: HUBC) (“HUB Security” or the “Company”), a global leader in confidential computing and secured data fabric technology, today announced a 1-for-10 reverse share split of its ordinary shares, no par value per share (the “Ordinary Shares”). The reverse share split and corresponding share capital adjustment will become effective at 11:59 p.m. Eastern Time on Friday, March 28, 2025. The Ordinary Shares will begin trading on a split-adjusted basis on The Nasdaq Stock Market LLC (“Nasdaq”) at the open of business on Monday, March 31, 2025, under the existing trading symbol “HUBC,” but the Ordinary Shares will trade under a new CUSIP number, M6000J168. HUB Security’s outstanding warrants will continue to be traded under the symbols “HUBCW” and “HUBCZ” and the CUSIP numbers for such warrants will remain unchanged.
As a result of the reverse share split, every 10 issued and outstanding Ordinary Shares will automatically be converted into one Ordinary Share. No fractional shares will be issued as a result of the reverse share split. Instead, in accordance with the Company’s Amended and Restated Articles of Association, all fractional shares will be rounded down to the nearest whole share. The reverse share split affects all shareholders uniformly and will not alter any shareholder’s percentage ownership interest in the Company’s issued and outstanding Ordinary Shares, except for adjustments that may result from the treatment of fractional shares.
The reverse share split will also affect the Company’s derivative securities, including outstanding notes, options, warrants and restricted share units (collectively, the “Outstanding Equity Rights”). Generally, the plans and other documents pertaining to the Outstanding Equity Rights include provisions providing for adjustments in the event of a reverse share split in order to maintain the same economic effect. Specifically, the exercise price and the number of Ordinary Shares issuable pursuant to Outstanding Equity Rights will be adjusted pursuant to the terms of such instruments in connection with the reverse share split.
The Company believes the reverse share split will increase the per share trading price of the Ordinary Shares and enable the Company to regain compliance with the minimum bid price requirement in Nasdaq Listing Rule 5450(a)(1).
HUB Cyber Security Resolves $16.6 Million in Legacy Liabilities through Strategic Settlements with Oppenheimer & Co. and Dominion Capital; Secures $13.5 Million Financing on Favorable Terms
TEL AVIV, Israel, Feb. 20, 2025 (GLOBE NEWSWIRE) — HUB Cyber Security Ltd.(NASDAQ: HUBC) (“HUB” or the “Company”), a global leader in confidential computing and advanced data fabric technology, has successfully executed important settlements with both Oppenheimer & Co. Inc. and Dominion Capital, eliminating $9.1 million in legacy liabilities. The Company has reduced a combined $16.6 million in claims to a final settlement amount of just $7.5 million, structured under highly favorable installment terms, significantly strengthening HUB’s balance sheet and financial flexibility.
To support these settlements, HUB has secured $13.5 million from Claymore Capital Pty Ltd. In exchange for long-term convertible notes, designed to fully fund the settlement obligations without requiring any cash outlay from HUB, as all payments under the settlements will be covered by Claymore. This highly favorable financing structure preserves liquidity, providing the Company with enhanced financial flexibility to focus on expansion and market growth. The five-year, zero-interest notes effectively refinance short-term liabilities from HUB’s balance sheet, reinforcing the Company’s commitment to long-term strategic financial management.
Noah Hershcoviz, CEO of HUB Cyber Security, commented:
“We are concluding a pivotal transitional period, successfully resolving significant legacy liabilities and eliminating obstacles that once limited our growth potential. Settling these obligations was a top priority for our management team upon joining HUB, and we are proud to have achieved this milestone. With these settlements behind us, HUB is now fully focused on executing our growth strategy. Following our transformative BlackSwan acquisition and a complete executive-level restructuring, we are entering our next phase with a clear strategic direction and a strong pipeline of opportunities. These transactions strengthen our financial foundation, position us to capitalize on growing market demand, and enhance our ability to create long-term value for our shareholders.”
MORE ABOUT THE COMPANY
HUB Security was established in 2017 by veterans of the elite intelligence units of the Israeli Defense Forces. The company specializes in unique cybersecurity solutions protecting sensitive commercial and government information. The company debuted an advanced encrypted computing solution aimed at preventing hostile intrusions at the hardware level while introducing a novel set of data theft prevention solutions. HUB operates in over 30 countries and provides innovative cybersecurity computing appliances as well as a wide range of cybersecurity professional services worldwide.
Delivers Essential Services To Global Blue-Chip Customers
120 experts specializing in Reliability Engineering, Safety, and Quality
300+ technology experts provide advanced software, testing, cybersecurity, and ICT services;
Comprehensive cybersecurity solutions to protect critical information and assets
In 2024, HUBC made significant strides in its strategic restructuring efforts, decisively closing underperforming businesses and optimizing its operations through targeted headcount reductions. The company believes these bold actions have transformed HUBC into a leaner, more agile organization, delivering tangible improvements in operational efficiency and setting a clear path toward sustained profitability.
The company’s products are already driving revenue growth, underscoring the market’s confidence in our solutions. Additionally, HUBC’srevitalized R&D team, led by the seasoned expertise of Mr. Nachman Geva, is accelerating innovation and ensuring that our offerings remain at the forefront of industry needs. HUBC is not just evolving—it is making real, impactful progress and optimizing every aspect of its business for a stronger, more dynamic future.
HUBC has successfully eliminated the majority of its high-cost debt, refinancing the business with long-term investors who share the company’s vision for sustainable growth.
These strategic actions are beginning to streamline HUBC’s liabilities and strengthen its balance sheet, providing enhanced financial flexibility to invest in high-growth opportunities, including the continued expansion of its Secured Data Fabric platform.
Big Data “Perfect Storm” Has Led to Data Fabric
AI generated data explosion – unprecedented volumes of data, overwhelming traditional systems
Cost efficiencies – legacy solutions are becoming prohibitively expensive to maintain and scale
Data silos and fragmentation – struggle with integrating diverse data sources
Need for real-time insights – businesses demand rapid access to insights
HUBC unifies all data, takes care of scalability, supports AI/ML, and is very cost-effective.
A unique platform featuring unbreakable, seamless, intelligent security
HUB’s SDF framework manages large volumes of sensitive data across diverse infrastructures, curring compliance and digital transformation costs by up to 50%
The SDF has already been successfully deployed in top European banks
Large pipeline of future customers across multiple industries
Unique synergies with IT services arm.
High software margins (+80%)
What is a Security Data Fabric?
Big data keeps getting bigger and security teams are struggling to leverage big data. This is because they have over a hundred security tools, often leading to millions of sensors that generate data in disparate and proprietary formats. Security Data Fabric helps to make sense of this data.
A security data fabric is a data fabric architecture that integrates and manages security data from various sources in a unified, secure, and governed approach.
HUB Professional Services
HUBC offers a broad portfolio of cybersecurity services and solutions worldwide, including managed services, compliance, and confidential computing. For over 30 years, HUB Security’s Professional Services division has protected information and assets for Fortune 500 companies, startups, and government agencies. Our state-of-the-art cybersecurity solutions are tailored to your industry, infrastructure, and applications, and include continuous risk assessments, ransomware resilience testing, incident response, and more. https://comsecglobal.com/
HUB Secure File Vault
About HUB Security’s Secure File Vault
HUB Security’s Secure File Vault represents a paradigm shift in data security. This innovative solution combines the power of a supercharged Managed File Transfer (MFT) system with dedicated hardware-driven security, creating a secure enclave to safeguard your organization’s data-driven workflows. In today’s business landscape, maintaining seamless digital interactions with customers, partners, suppliers, and subcontractors is fundamental. However, this continuous digital engagement also exposes organizations to the ever-increasing risks of cyberattacks and data breaches.
Why is the Secure File Vault Needed?
In an era where cyber threats and data breaches are on the rise, organizations must adopt innovative security solutions that not only simplify workflows but also protect sensitive data and ensure compliance with regulations. Despite extensive mitigation efforts, targeted data breaches remain a significant challenge, leading to financial losses, reputational damage, and legal complications. Traditional data protection mechanisms are often unable to keep pace with evolving threats. Secure File Vault addresses this pain point by providing a solution that surpasses the limitations of conventional MFT solutions.
How Does Secure File Vault Work?
Secure File Vault’s significance lies in its ability to provide an extra layer of security beyond traditional MFT solutions. It does so by integrating hardware-based secure enclaves into the data management process. These enclaves create controlled and isolated computing environments where data and applications are processed securely, shielded from unauthorized access, malicious actors, vulnerabilities, and network risks. This approach ensures data confidentiality and integrity even when the entire organizational infrastructure is compromised. HUB Secure File Vault Offers Several Unique Benefits:
Attack Surface Management – ASM
Consistently identify and address both your recognized and unforeseen external risks HUB Security’s Attack Surface Management provides you with insights into your genuine attack surface, encompassing the digital assets you acknowledge, those you might not be aware of, and any potentially harmful or unauthorized assets
What types of security issues can HUB Security identify in my external digital assets?
Certificate Authority issues
Compromised Credentials
Email Security issues
Exploitable Ports
Exposed Cloud Storage
Exposed Web Interfaces
Hijackable Subdomains
Mail Servers In Blocklist
SSL/TLS issues
Obtain the perspective of potential attackers!
To safeguard your organization, it’s essential to have a clear understanding of the assets and digital terrain requiring protection. While conducting vulnerability scans on known assets is straightforward, monitoring newly added assets within your infrastructure can be challenging.
HUBC’s Attack Surface Monitoring & Management offers automated, comprehensive insight into your digital footprint, revealing security concerns and vulnerabilities that could be targeted by potential adversaries.
Why HUBC Needs to be #1 on Your Screen Wednesday
Over 500 customers including tier 1 customers such as Boeing, Visa, Lockheed Martin, BNP Paribas and more! The Secured Data Fabric platform is the Company’s primary growth engine. This cutting-edge technology consolidates data from multiple silos into a unified, secure system that enables clients to navigate vast data pools, ensure compliance, and protect sensitive information with advanced encryption. HUBC’s solution stands apart from traditional data lake systems by securely retrieving data in real-time, offering a transformative approach that reduces costs and mitigates security vulnerabilities. This unique value proposition has driven strong demand, reflected in a significant increase in our backlog and a surge in RFPs from both existing and new clients. HUBC’s legacy IT services business provides a stable foundation with longstanding relationships across key sectors. The Company’s trusted advisor role to global enterprises enables HUBC to cross-sell its innovative solutions into these well-established accounts. It anticipates keeping a steady growth in the turnover and keeping the momentum in optimizing its margins. Recent achievements highlight HUBC’s growing influence and reliability in the market. In 2024, the company renewed partnership with a subsidiary of a major credit card service provider, securing a six-figure contract to enhance risk management and compliance measures. This demonstrates the company’s trusted role in safeguarding critical financial data. HUBC has secured two government contracts and won a $2 million contract with the Israel Airports Authority, showcasing its strategic growth within the cybersecurity domain. HUBC entered a landmark five-year agreement with Blackswan Technologies Ltd., a leading U.S. enterprise-AI vendor. This collaboration aims to provide state-of-the-art transaction monitoring and cyber risk mitigation solutions for a top-tier European bank, reflecting the company’s strategic expansion into the finance sector. Financially, HUBC is on solid ground. In April 2024, the company successfully secured $8 million through a straight debt financing arrangement. This influx of capital supports HUB’s strategic investments and growth initiatives. Most recently HUBC successfully restructured $7 million, more than 60% of its secured debt. The company has acquired QPOINT, a firm with annual revenues exceeding $26 million, adding over 100 top-tier customers to HUBC’s portfolio. HUBC’s client base includes high-profile names such as Rafael Advanced Defense Systems, the developer of Israel’s ‘Iron Dome,’ underscoring the company’s capability to deliver critical security solutions at a national level. The company’s commitment to excellence and innovation continues to drive its success and market expansion.
High Profile Chinese Hacking Incidents Have Made Cybersecurity a Buzz Worthy Topic Again!
The “Salt Typhoon” Chinese hacking incident in 2024, which targeted U.S. telecom companies, could drive higher spending on cybersecurity says one analyst.
Salt Typhoon is the name given to a Chinese hacking group that has compromised at least nine U.S. telecommunications firms, reportedly hacked into the phones of President-elect Donald Trump and Vice President-elect JD Vance and collected geolocation data for hundreds of phones based around Washington D.C.!
Atop federal cybersecurity official said in January 2025 that threat hunters from the Cybersecurity and Infrastructure Security Agency first discovered activity from Salt Typhoon on federal networks, allowing public and private sector defenders to more quickly “connect the dots” and respond to Chinese attacks on the U.S. telecommunications industry.
These attacks have occurred despite the Biden administration worked to improve communications with China!
You may remember in the early hours of July 19; a well-known cybersecurity company CrowdStrike (CRWD) published a faulty software update that temporarily disabled more than 8.5 million PCs that use its services. This chaotic outage resulted in problems across banking, health care and many other industries.
What the outage also did was bring more awareness to just how important cybersecurity is and to the potential value of cybersecurity stocks.
U.S. policymakers and the private sector are now faced with the challenge to secure the best cybersecurity solutions. U.S. regulators and lawmakers are even proposing new rules to protect hospitals from cyberattacks in 2025 after a bruising year of hacks and software outages.
According to current projections, the cybersecurity market is expected to reach a value of approximately $403 billion by 2027, highlighting the significant growth and increasing demand for robust cybersecurity solutions as cyber threats evolve rapidly.
Key points about this prediction:
Market Expansion:
This substantial growth is driven by the growing reliance on digital systems across industries, making cybersecurity a crucial priority for businesses and organizations.
Outsourcing Trend:
A significant portion of this value is anticipated to come from the cybersecurity outsourcing market, where companies increasingly seek external expertise to manage complex security challenges.
Evolving Threats:
The ever-changing landscape of cyber threats, including sophisticated ransomware attacks and advanced persistent threats, is further fueling the demand for advanced cybersecurity solutions.
HUB Cyber Security Completes Acquisition of BlackSwan Technologies to Drive AI-Powered Data Solutions for Global Enterprises
This strategic acquisition positions HUB to capitalize on a projected $12.91 billion market by 2032 and deliver advanced security, compliance, and regulatory technologies to banks, fintechs, and governments worldwide.
TEL AVIV, Israel, Jan. 27, 2025 (GLOBE NEWSWIRE) — via IBN – HUB Cyber Security Ltd.(NASDAQ: HUBC) (“HUB” or the “Company”), a global leader in advanced cybersecurity and data fabric technology, is pleased to announce the closing of its highly anticipated acquisition of BlackSwan Technologies, Inc. (“BlackSwan”).
HUB believes that the acquisition of BlackSwan will solidify its position as a leading provider of secured data fabric solutions, offering a critical safeguard for banks, financial institutions and other industries navigating an increasingly complex regulatory and cybersecurity environment. The combined operations of HUB and BlackSwan seek to address a market opportunity believed to exceed $12.91 billion, with significant growth anticipated in 2025 and 2026, fueled by rising customer demands and stricter regulatory requirements.
BlackSwan’s solutions are trusted by large global banks, fintech firms, and governments. The two companies have collaborated for the past six months and are working together to close new contracts in regulatory tech and other critical use cases. With an established presence in Germany, the UK, Sri Lanka, Poland and Israel, BlackSwan brings a diverse, global customer experience and extensive market reach.
Noah Hershcoviz, CEO of HUB Cyber Security, stated, “This acquisition marks a pivotal milestone for HUB, strengthening our position as a leader in secured data management and compliance solutions. We strongly believe BlackSwan’s innovative technologies will enable us to deliver unparalleled value to our clients, particularly in the financial sector, where the demand for robust security and compliance is especially high. With over $50 million invested in BlackSwan’s cutting-edge solutions, we are eager to bring this superior technology to our clients. Our projected revenues from the combined operations are expected to grow significantly and deliver additional bookings of over $25 million in 2025, driven by new customer acquisitions and enhanced operational synergies”.
HUB Security Announces $3.3 Million Investment to Accelerate Corporate Growth
TEL AVIV, Israel, Aug. 19, 2024 (GLOBE NEWSWIRE) — via IBN – HUB Cyber Security Ltd. (NASDAQ: HUBC), a developer of confidential computing cybersecurity solutions and advanced data fabric (“HUB Security” or the “Company”), is pleased to announce the successful completion of a $3.3 million private placement from non-U.S. investors.
This investment is in the form of convertible notes with a conversion price of $0.70 per share. As part of the transaction, the Company has also issued warrants with an exercise price of $1.00 per share.
In parallel, HUB Security is engaged in discussions to extend the maturity date of a $4.0 million principal note, originally due in August 2024, as part of its broader financial strategy.
Noah Hershcoviz, CEO of HUB, commented, “We are pleased to secure an investment from a group of esteemed investors who value our strategic vision and operational strengths. This capital will enable us to advance our growth initiatives and continue to deliver value to our stakeholders as we expand our market presence.”
Mr. Noah Hershcoviz joined HUB Security as the Chief Strategy Officer and became a member of the company’s Board of Directors on October 4, 2023. Noah Hershcoviz brings a wealth of financial and execution expertise, with a background that includes roles in the M&A division of Ernst & Young (EY) and as an investment banking executive in various capacities. He boasts a distinguished track record of managing investments and consistently exceeding market performance benchmarks. With a proven history of successfully guiding companies through initial public offerings, mergers and acquisitions, and reverse takeovers, Mr. Hershcoviz embodies an entrepreneurial spirit coupled with a global perspective on business transformation. His leadership is expected to play a pivotal role in charting the vision and strategic direction of the company, bringing innovative and industry-leading approaches.
Osher Partok Rheinisch
Chief Legal Officer
Osher Partok Rheinisch has more than 20 years of commercial, corporate and compliance legal experience. She was admitted to both the Israel and the New York State Bars and is a member of the Association of Corporate Counsels and the International Association of Privacy Professionals where she holds CIPP/E, CIPM and FIP authorizations. Prior to joining HUB Security, Osher was the General Counsel at Orgenesis (NASDAQ: ORGS) and the Compliance Counsel of Amdocs (NASDAQ: DOX). Osher holds an LLB and an MBA from Tel Aviv University.
Nir Bar-Eli
CEO of Comsec Global
Mr. Bar-Eli has over 20 years of experience managing sales organizations for large companies. Before becoming Comsec’s CEO, Mr. Bar-Eli served as the CEO of Comsec Distribution Ltd., another of the Company’s subsidiaries, since 2014. Prior to joining Comsec Distribution, Mr. Bar-Eli served as Head of Channels at Check Point Software Technologies Ltd from 2008 to 2014 and as the Head of Sales for Bynet Data Communication from 2001 to 2008. Mr, Bar-Eli has a B.A. in Business Management from Champlain University and studied Engineering and Management from Tel Aviv University.
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SIX THOUSAND FIVE HUNDRED USD BY SIDEWAYS FREQUENCY LLC FOR A ONE DAY HUBC AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
